<SEC-DOCUMENT>0001104659-25-057298.txt : 20250606
<SEC-HEADER>0001104659-25-057298.hdr.sgml : 20250606
<ACCEPTANCE-DATETIME>20250606160138
ACCESSION NUMBER:		0001104659-25-057298
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250606
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250606
DATE AS OF CHANGE:		20250606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEGA HEALTHCARE INVESTORS INC
		CENTRAL INDEX KEY:			0000888491
		STANDARD INDUSTRIAL CLASSIFICATION:	REAL ESTATE INVESTMENT TRUSTS [6798]
		ORGANIZATION NAME:           	05 Real Estate & Construction
		EIN:				383041398
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11316
		FILM NUMBER:		251030437

	BUSINESS ADDRESS:	
		STREET 1:		303 INTERNATIONAL CIRCLE,
		STREET 2:		SUITE 200
		CITY:			HUNT VALLEY
		STATE:			MD
		ZIP:			21030
		BUSINESS PHONE:		410-427-1700

	MAIL ADDRESS:	
		STREET 1:		303 INTERNATIONAL CIRCLE,
		STREET 2:		SUITE 200
		CITY:			HUNT VALLEY
		STATE:			MD
		ZIP:			21030
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2517197d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ohi="http://omegahealthcare.com/20250606">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_ohi_omegahealthcare.com_20250606 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20250606_20250606 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0000888491 -->
<!-- Field: Set; Name: xdx; ID: xdx_071_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\EntityInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000005" name="dei:EntityCentralIndexKey">0000888491</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ohi-20250606.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000888491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-06</xbrli:startDate>
        <xbrli:endDate>2025-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 2in"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20250606__20250606_z72NBpdPBj16"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000011" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 2in"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_906_edei--DocumentPeriodEndDate_c20250606__20250606_zZsR2GUIkFbg"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt:datemonthdayyearen" id="Fact000012" name="dei:DocumentPeriodEndDate">June 6, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20250606__20250606_z8eqm8bQ9mG5"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000013" name="dei:EntityRegistrantName">OMEGA HEALTHCARE INVESTORS, INC.</ix:nonNumeric></span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20250606__20250606_zQ3IoT0qZBB6"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt-sec:stateprovnameen" id="Fact000014" name="dei:EntityIncorporationStateCountryCode">Maryland</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20250606__20250606_zEiikjXoHNel"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000015" name="dei:EntityFileNumber">1-11316</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20250606__20250606_zvJvSJiDRHt8"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000016" name="dei:EntityTaxIdentificationNumber">38-3041398</ix:nonNumeric></span></b></span></td></tr>


<tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">(State or other jurisdiction of<br/>
 incorporation)</span></td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250606__20250606_zmRZLEmPxMDc"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000017" name="dei:EntityAddressAddressLine1">303 International Circle,</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine2_c20250606__20250606_zTooOCn6O7N1"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000018" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20250606__20250606_z3EcYaBwJLX2"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000019" name="dei:EntityAddressCityOrTown">Hunt Valley</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20250606__20250606_zXIOyOnkK10f"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250606__20250606_z6fkEssZVPLi"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000021" name="dei:EntityAddressPostalZipCode">21030</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
/ Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_908_edei--CityAreaCode_c20250606__20250606_z0eF1zRKruhj"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000022" name="dei:CityAreaCode">410</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20250606__20250606_zMp7t9UqxtWg"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000023" name="dei:LocalPhoneNumber">427-1700</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20250606__20250606_zxxj9tZlmZM6"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt:booleanfalse" id="Fact000024" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_905_edei--SolicitingMaterial_c20250606__20250606_zngzkz49ABp1"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt:booleanfalse" id="Fact000025" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20250606__20250606_zTRmAY2ULwb7"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20250606__20250606_zAhi8Zr0G1z8"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt:booleanfalse" id="Fact000027" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities registered pursuant to Section
12(b) of the Securities Exchange Act of 1934:</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; border-image: none; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20250606__20250606_zGJMZSc7ddMd"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000028" name="dei:Security12bTitle">Common Stock, $.10 par value</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20250606__20250606_zZDK18BgEop5"><ix:nonNumeric contextRef="AsOf2025-06-06" id="Fact000029" name="dei:TradingSymbol">OHI</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20250606__20250606_zAKIYbuTA5D7"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&#160;<span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20250606__20250606_z9IwKls0tYEg"><ix:nonNumeric contextRef="AsOf2025-06-06" format="ixt:booleanfalse" id="Fact000031" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif"><b>Item 5.</b></span><b>03</b></td><td><b>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">On June 6, 2025, Omega
Healthcare Investors, Inc. (&#8220;Omega&#8221; or the &#8220;Company&#8221;) held its 2025 Annual Meeting of Stockholders (the &#8220;Annual
Meeting&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">At the Annual Meeting,
Omega&#8217;s stockholders, upon the unanimous recommendation of the Board of Directors, approved an amendment to the Omega Healthcare
Investors, Inc. Articles of Amendment and Restatement to increase the number of authorized shares of common stock, $0.10 par value per
share, from 350,000,000 shares to 700,000,000 shares (the &#8220;Amendment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">A summary of the Amendment
was included as part of Proposal 4 in Omega&#8217;s definitive proxy statement filed with the Securities and Exchange Commission on April
22, 2025, as amended. The summary of the Amendment contained in the proxy statement is qualified by and subject to the full text of the
Amendment, which is included in the Company&#8217;s Articles of Amendment and Restatement, as amended, and filed as Exhibit 3.1 to this
Current Report and incorporated herein by reference.</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 5.07</b></td><td><b>Submission of Matters to a Vote of Security Holders. </b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">At the Annual Meeting,
the holders of 242,057,737 shares of Omega&#8217;s common stock were present in person or represented by proxy, representing approximately
84.29% of the total outstanding common stock as of the record date for the meeting. The final results for each of the matters submitted
to a vote of stockholders at the Annual Meeting are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Proposal 1: Election of Directors </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">For</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Against</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Abstentions</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Broker<br/>
Non-Votes</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 28%"><span style="font-size: 10pt">Kapila K. Anand</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">191,867,831</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">7,007,593</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">428,665</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Craig R. Callen</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">191,605,157</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7,266,315</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">432,617</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Lisa C. Egbuonu-Davis</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">194,618,346</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4,022,649</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">663,094</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Barbara B. Hill</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">192,199,888</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">6,416,848</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">687,353</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Kevin J. Jacobs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">196,157,915</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2,718,367</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">427,807</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">C. Taylor Pickett</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">195,393,992</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3,491,346</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">418,751</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Stephen D. Plavin</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">188,019,184</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10,868,304</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">416,601</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Burke W. Whitman</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">193,917,650</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4,968,308</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">418,131</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42,753,648</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Proposal 2: Proposal to Ratify the Selection
of Ernst &amp; Young LLP as Omega&#8217;s Independent Auditor for Fiscal Year 2025 </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 27%; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">For</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Against</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 23%; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Abstentions</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 23%; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Broker Non-Votes</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt">230,705,879</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10,808,358</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">543,500</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Not applicable</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Proposal 3: Advisory Vote
on Executive Compensation </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 27%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">For</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Against</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 23%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Abstentions</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 23%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Broker Non-Votes</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">190,077,014</span></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">8,122,265</span></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">1,104,810</span></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">42,753,648</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Proposal 4: Amendment to Omega&#8217;s
Charter to Increase the Number of Authorized Shares of Its Common Stock </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 27%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">For</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Against</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 23%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Abstentions</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 23%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Broker Non-Votes</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">231,662,341</span></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">8,905,260</span></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">1,490,136</span></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Not applicable</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the director nominees was elected, the
selection of Ernst &amp; Young LLP was ratified, Omega&#8217;s executive compensation was approved on an advisory basis, and Omega&#8217;s
charter amendment to increase the number of authorized shares of common stock was approved.</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 7.01</b></td><td><b>Regulation FD Disclosure. </b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective as of the completion of the Annual Meeting,
Mr. Plavin was appointed to serve on the Investment Committee, in place of Mr. Pickett, and no longer serves on the Compensation Committee.
The membership of the Board&#8217;s standing committees is as set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Members:
</span>Kapila K. Anand (Chair), Craig R. Callen, Kevin J. Jacobs and Burke W. Whitman</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Members:
</span>Burke W. Whitman (Chair), Barbara B. Hill and Dr. Lisa C. Egbuonu-Davis</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Investment Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Members:
</span>Craig R. Callen (Chair), Kapila K. Anand, Kevin J. Jacobs and Stephen D. Plavin</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Nominating and Corporate Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Members:
</span>Stephen D. Plavin (Chair), Craig R. Callen, Dr. Lisa C. Egbuonu-Davis and Barbara B. Hill</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 9.01</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>(d)</b></td><td><b>Exhibits</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.3in">&#160;</td>
    <td style="width: 0.7in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><a href="tm2517197d2_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></a></td>
    <td><a href="tm2517197d2_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Amendment and Restatement of Omega Healthcare Investors, Inc., as amended through June 6, 2025.</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span><span style="font-size: 10pt">.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -1.25in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -1.25in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif">OMEGA HEALTHCARE INVESTORS, INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">Dated: June 6, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Gail D. Makode</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Gail D. Makode</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chief Legal Officer, General Counsel</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 229.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 229.5pt"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 229.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 229.5pt">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUq3JPAxqYgsQiJ63XKKJd2R2c3yk/rLViUaBobh3nOvECOxppUukeG8yDM4YlWXyiHkeENGc0XvSDfbBPzN8a6tY2Vc//7AlDyDnonHUl680FsbbbFIIIwn02giZxDKJJrDYSeCTk/J3HSBxmlVgjIFHJhq1ugUt0PCUb3JUNX2VSdkq8kkEI3DQf6ADCMJe2rUi/hhIctSEYz6CcSa6Vl71/Lt0HQkLEusfJ0d6P8GXwZJSow= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2517197d2_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>OMEGA HEALTHCARE INVESTORS, INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>OMEGA HEALTHCARE INVESTORS,
INC.</B>, a Maryland corporation (hereinafter called the &#8220;<B>Corporation</B>&#8221;), certifies to the State Department of Assessments
and Taxation of Maryland, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FIRST:&nbsp;</B>The Corporation desires to
amend the charter of the Corporation (the &#8220;<B>Charter</B>&#8221;) as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SECOND:&nbsp;</B>The Charter of the Corporation
shall be and hereby is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.01 of the Charter
is hereby deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B>Section 4.01 Authorized Shares.</B>&nbsp;The
total number of shares of capital stock that the Corporation shall have authority to issue is Seven Hundred Twenty Million (720,000,000),
of which Seven Hundred Million (700,000,000) shall be shares of Common Stock having a par value of $0.10 per share and Twenty Million
(20,000,000) shall be shares of Preferred Stock having a par value of $1.00 per share. The aggregate par value of all said shares shall
be Ninety Million Dollars ($90,000,000). The Board of Directors shall have the authority to authorize the issuance of Common Stock or
Preferred Stock from time to time in such amounts and for such consideration as the Board of Directors shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIRD:&nbsp;</B>Immediately before the amendment
herein, the Corporation had the authority to issue 370,000,000 total shares of capital stock, of which 350,000,000 shares of common stock
having a par value of $0.10 per share and 20,000,000 shares of preferred stock having a par value of $1.00 per share were authorized.
The aggregate par value of all shares of capital stock authorized immediately before the amendment was $55,000,000. As amended, the total
number of authorized shares of stock of all classes, the number of shares of each class, the par value of each class of shares, and the
aggregate par value of all shares of all classes is set forth above in Article SECOND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FOURTH:&nbsp;</B>The description of each class
of shares, including preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications,
and terms and conditions of redemption, was not changed by these Articles of Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FIFTH:&nbsp;</B>The foregoing amendment to
the Charter of the Corporation has been duly advised by the Board of Directors of the Corporation via unanimous written consent dated
January 2, 2025, and approved by the stockholders of the Corporation in accordance with the Charter and Section 2-604 of the Maryland
General Corporation Law at the Annual Meeting of Stockholders held on June 6, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SIXTH: </B>The undersigned officer acknowledges
these Articles of Amendment to be the corporate act of the Corporation and, as to all matters or facts required to be verified under oath,
the undersigned acknowledges that, to the best of such officer&#8217;s knowledge, information and belief, these matters and facts are
true in all material respects and that this statement is made under the penalties of perjury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN
WITNESS WHEREOF, </B>the Corporation has caused these Articles of Amendment to be signed in its name and on its behalf by its Chief
Financial Officer, Treasurer and Assistant Secretary and attested to by its Chief Legal Officer, General Counsel and Secretary on
this 6th day of June, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="5"><B>OMEGA HEALTHCARE INVESTORS, INC.</B> &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="5">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>ATTESTED TO BY:</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>SIGNED BY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Gail D. Makode</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Robert O. Stephenson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 43%">Gail D. Makode</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 43%">Robert O. Stephenson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Legal Officer, General Counsel and Secretary&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer, Treasurer and Assistant Secretary</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OMEGA HEALTHCARE INVESTORS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES SUPPLEMENTARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OMEGA HEALTHCARE INVESTORS, Inc., a Maryland corporation
(the &ldquo;<B>Corporation</B>&rdquo;), hereby certifies to the State Department of Assessments and Taxation of Maryland (the &ldquo;<B>Department</B>&rdquo;),
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FIRST</B>:&nbsp;&nbsp;Pursuant to Section 3-802(c)
of the Maryland General Corporation Law (the &ldquo;<B>MGCL</B>&rdquo;), the Board of Directors of the Corporation (the &ldquo;<B>Board
of Directors</B>&rdquo;), duly adopted a resolution, at a meeting duly called and held on November 1, 2019, that prohibits the Corporation
from electing to be subject to Section 3-803 of the MGCL unless such election is first approved by the stockholders of the Corporation
by the affirmative vote of a majority of all the votes entitled to be cast on the matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SECOND</B>:&nbsp;&nbsp;These Articles Supplementary
have been approved by the Board of Directors in the manner and by the vote required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIRD</B>:&nbsp;&nbsp;These Articles Supplementary
shall be effective upon the acceptance of these Articles Supplementary for record by the Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FOURTH</B>:&nbsp;&nbsp;&nbsp;The undersigned
Chief Executive Officer of the Corporation acknowledges these Articles Supplementary to be the corporate act of the Corporation and, as
to all matters or facts required to be verified under oath, the undersigned Chief Executive Officer acknowledges that to the best of his
knowledge, information and belief, these matters and facts are true in all material respects and that this statement is made under the
penalties of perjury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signatures page follows.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Corporation has
caused these Articles Supplementary to be executed under seal in its name and on its behalf by its Chief Executive Officer, and attested
to by its Chief Financial Officer, as of this 5th day of November, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ATTEST</B>:<B>OMEGA HEALTHCARE INVESTORS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 43%">/s/ Robert O. Stephenson</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 6%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 43%">/s/ C. Taylor Pickett</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Name:</TD>
  <TD STYLE="text-align: justify">Robert O. Stephenson</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">Name:</TD>
  <TD STYLE="text-align: justify">C. Taylor Pickett</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Title:</TD>
  <TD STYLE="text-align: justify">Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">Title:</TD>
  <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>OMEGA HEALTHCARE INVESTORS, INC.</B>,
a Maryland corporation having its principal place of business at 200 International Circle, Suite 3500, Hunt Valley, Maryland 21030
(hereinafter called the &ldquo;<B>Corporation</B>&rdquo;), hereby certifies to the State Department of Assessments and Taxation
of Maryland, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FIRST: </B>The Corporation desires to
amend its Charter as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECOND: </B>The Charter of the Corporation is hereby amended
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.03(b) of the Charter of the Corporation
is hereby deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the other provisions of this Section 5.03(b), the Board of Directors is and shall remain classified into three (3) groups of
Directors, with the Directors of each class serving for a term expiring at the Annual Meeting of Stockholders held during the third
(3rd) year after election (except as set forth in this Section 5.03(b)) and until his or her successor shall have been duly elected
and shall have qualified. Effective as of the 2015 Annual Meeting of Stockholders, the terms of newly elected Directors shall be
as follows: (i) the Directors&rsquo; elected to hold office at the 2015 Annual Meeting of Stockholders shall hold office for a
term expiring at the Annual Meeting of Stockholders to be held in 2016; (ii) at the Annual Meeting of Stockholders to be held in
2016, the Directors whose terms expire at that meeting or such Directors&rsquo; successors shall be elected to hold office for
a term expiring at the Annual Meeting of Stockholders to be held in 2017; and (iii) at the Annual Meeting of Stockholders to be
held in 2017 and at each Annual Meeting of Stockholders thereafter, all Directors shall be elected to hold office for a term expiring
at the next Annual Meeting of Stockholders. The classification of the Board of Directors shall terminate at the Annual Meeting
of Stockholders to be held in 2017 and, thereafter, all Directors shall be elected in accordance with clause (iii) above. In no
event may any Director be removed from office without cause. The names of the current Directors who shall serve until the next
Annual Meeting of Stockholders in the year when their respective term expires and until their successors are duly elected and qualify
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Thomas F. Franke</TD>
    <TD STYLE="width: 50%">(Term to expire in 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Bernard J. Korman</TD>
    <TD>(Term to expire in 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Craig R. Callen</TD>
    <TD>(Term to expire in 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Norman R. Bobins</TD>
    <TD>(Term to expire in 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Edward Lowenthal</TD>
    <TD>(Term to expire in 2016)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Stephen D. Plavin</TD>
    <TD>(Term to expire in 2016)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ben W. Perks</TD>
    <TD>(Term to expire in 2016)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Craig M. Bernfield</TD>
    <TD STYLE="width: 50%">(Term to expire in 2017)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Barbara B. Hill</TD>
    <TD>(Term to expire in 2017)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Harold J. Kloosterman</TD>
    <TD>(Term to expire in 2017)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>C. Taylor Pickett</TD>
    <TD>(Term to expire in 2017)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FOURTH: </B>The description of each
class of shares, including preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends,
qualifications, and terms and conditions of redemption, was not changed by these Articles of Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FIFTH: </B>The foregoing amendments
to the Charter of the Corporation have been advised by the Board of Directors at a board meeting held on October 30, 2014 and approved
by the stockholders of the Corporation in accordance with Section 2-604 of the Maryland General Corporation Law at the Annual Meeting
of Stockholders held on July 17, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature Page Follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF, </B>the Corporation
has caused these Articles of Amendment to be signed in its name and on its behalf by its President and Chief Executive Officer
and attested to by its Assistant Secretary on this 17<SUP>th</SUP> day of July, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>ATTEST:</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>OMEGA HEALTHCARE INVESTORS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>By:</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Robert O. Stephenson</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ C. Taylor Pickett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>C. Taylor Pickett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Assistant Secretary</TD>
    <TD>&nbsp;</TD>
    <TD>Title: </TD>
    <TD>President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE UNDERSIGNED, President and Chief Executive
Officer of OMEGA HEALTHCARE INVESTORS, INC., who executed on behalf of the Corporation the foregoing Articles of Amendment of which
this certificate is made a part, hereby acknowledges in the name and on behalf of said Corporation the foregoing Articles of Amendment
to be the corporate act of said Corporation and hereby certifies that to the best of his knowledge, information, and belief the
matters and facts set forth therein with respect to the authorization and approval thereof are true in all material respects under
the penalties of perjury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%">/s/ C. Taylor Pickett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>C. Taylor Pickett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLES OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>OMEGA HEALTHCARE INVESTORS, INC.</B>, a
Maryland corporation having its principal place of business at 200 International Circle, Suite 3500, Hunt Valley, Maryland 21030
(hereinafter called the &ldquo;<B>Corporation</B>&rdquo;), hereby certifies to the State Department of Assessments and Taxation
of Maryland, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FIRST: </B>The Corporation desires to amend
its Charter as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECOND: </B>The Charter of the Corporation is hereby amended
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>A. </B>Section 4.01 of the Charter of the
Corporation is hereby deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in"><B>Section 4.01 Authorized Shares.</B> The total number of
shares of capital stock that the Corporation shall have authority to issue is Three Hundred Seventy Million (370,000,000), of which
Three Hundred Fifty Million (350,000,000) shall be shares of Common Stock having a par value of $.10 per share and Twenty Million
(20,000,000) shall be shares of Preferred Stock having a par value of $1.00 per share. The aggregate par value of all said shares
shall be Fifty-Five Million Dollars ($55,000,000). The Board of Directors shall have the authority to authorize the issuance of
Common Stock or Preferred Stock from time to time in such amounts and for such consideration as the Board of Directors shall deem
appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>B: </B>Section 7.02(b) of the Charter of
the Corporation is hereby deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any
of the provisions of these Articles or the Bylaws of the Corporation (and notwithstanding the fact that a lesser percentage may
be specified by law, these Articles or the Bylaws of the Corporation), the repeal or amendment of any provision of Section 5.02,
Section 5.03(a), Section 5.04, Section 5.05 or this Section 7.02(b) shall be valid only if declared advisable by the Board of Directors
and approved by the affirmative vote of holders of not less than 80% of the total number of votes entitled to be cast thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THIRD: </B>Immediately before the amendments
herein, the Corporation had the authority to issue 220,000,000 total shares of capital stock, of which 200,000,000 shares of common
stock having a par value of $0.10 per share and 20,000,000 shares of preferred stock having a par value of $1.00 per share were
authorized. The aggregate par value of all shares of capital stock authorized immediately before the amendments was $40,000,000.
As amended, the total number of authorized shares of stock of all classes, the number of shares of each class, the par value of
each class of shares, and the aggregate par value of all shares of all classes is set forth above in Article SECOND, Part A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FOURTH: </B>The description of each class
of shares, including preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications,
and terms and conditions of redemption, was not changed by these Articles of Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FIFTH: </B>The foregoing amendments to the
Charter of the Corporation have been advised by the Board of Directors at a board meeting held on October 30, 2014 and adopted
by the stockholders of the Corporation in accordance with Section 2-604 of the Maryland General Corporation Law at a special meeting
of stockholders held on March 27, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>[Signature Page Follows]</B></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>IN WITNESS WHEREOF, </B>the Corporation
has caused these Articles of Amendment to be signed in its name and on its behalf by its President and Chief Executive Officer
and attested to by its Secretary on this 1<SUP>st</SUP> day of April, 2015.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>ATTEST:</B></TD>
    <TD COLSPAN="3"><B>OMEGA HEALTHCARE INVESTORS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-decoration: none; width: 30%">/s/ Daniel J. Booth</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%">/s/ C. Taylor Pickett</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="3">Name:&nbsp;&nbsp;C. Taylor Pickett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Secretary</TD>
    <TD COLSPAN="3">Title: President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THE UNDERSIGNED, President and Chief Executive
Officer of OMEGA HEALTHCARE INVESTORS, INC., who executed on behalf of the Corporation the foregoing Articles of Amendment of which
this certificate is made a part, hereby acknowledges in the name and on behalf of said Corporation the foregoing Articles of Amendment
to be the corporate act of said Corporation and hereby certifies that to the best of his knowledge, information, and belief the
matters and facts set forth therein with respect to the authorization and approval thereof are true in all material respects under
the penalties of perjury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-decoration: none">/s/ C. Taylor Pickett</TD>
    <TD STYLE="text-decoration: none; width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: C. Taylor Pickett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLES
OF AMENDMENT AND RESTATEMENT</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>OMEGA
HEALTHCARE INVESTORS, INC.</B>, a Maryland corporation having its principal office c/o The Corporation Trust Incorporated, 351
West Camden Street, Baltimore, Maryland 21201 (hereinafter called the &#8220;<B>Corporation</B>&#8221;), hereby certifies to the
State Department of Assessments and Taxation of Maryland, that:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">FIRST:
The Corporation desires to amend and restate its charter as currently in effect.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">SECOND:&#160;&#160;The
provisions of the charter now in effect, as amended hereby in accordance with the MGCL, are as follows (capitalized terms used
but not defined in these Articles shall have the respective meanings ascribed to them in Section 5.02, Section 5.04(a) and Section
7.01 hereof):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
I</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>NAME</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">The
name of the Corporation is:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0">Omega
Healthcare Investors, Inc.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
II</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>PURPOSES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">The
purpose for which the Corporation is formed is to engage in any lawful act or activity for which corporations may be organized
under the MGCL as now or hereafter in force, including, without limitation or obligation, the ownership and leasing of real property,
the ownership of mortgages secured by interests in real property and, subject to the provisions of Section 5.04(l), engaging in
business as a REIT.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
III</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>PRINCIPAL
OFFICE AND RESIDENT AGENT</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">The
address of the principal office of the Corporation in the State of Maryland is c/o The Corporation Trust Incorporated, 351 West
Camden Street, Baltimore, Maryland 21201. The name of the resident agent of the Corporation in the State of Maryland is The Corporation
Trust Incorporated, and the address is 351 West Camden Street, Baltimore, Maryland 21201.&#160;&#160;The Corporation may maintain
an office or offices in such other place or places as may be, from time to time, fixed by its Board of Directors or as may be fixed
by the Bylaws.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
IV</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>CAPITAL
STOCK</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
4.01&#160;&#160;&#160;&#160;&#160;&#160;&#160; Authorized Shares.</B>&#160;&#160;The total number of shares of capital stock that
the Corporation shall have authority to issue is Two Hundred Twenty Million (220,000,000), of which Two Hundred Million (200,000,000)
shall be shares of Common Stock having a par value of $.10 per share and Twenty Million (20,000,000) shall be shares of Preferred
Stock having a par value of $1.00 per share, of which 4,739,500 shares are designated as 8.375% Series D Cumulative Redeemable
Preferred Stock (the &#8220;Series D Preferred&#8221;), with the preferences, rights, voting powers, restrictions, limitations
as to dividends, qualifications and terms and conditions of redemption of such Series D Preferred as set forth on Exhibit A attached
hereto and made a part hereof.&#160;&#160;The aggregate par value of all said shares shall be Forty Million Dollars ($40,000,000).&#160;&#160;The
Board of Directors shall have the authority to authorize the issuance of Common Stock or Preferred Stock from time to time in such
amounts and for such consideration as the Board of Directors shall deem appropriate.</P>






<P>&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
4.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preferred Stock</B>.&#160;&#160;The Board of Directors shall have the
authority to authorize from time to time the issuance of Preferred Stock in one or more series as the Board of Directors shall
deem appropriate, and to fix the rights, powers and restrictions of the Preferred Stock by resolution and the filing of articles
supplementary. Such authority shall include, but not be limited to, the designation of the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(a)&#160;&#160;&#160;the
number of shares constituting such series and the distinctive designation thereof;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">(b)&#160;&#160;&#160;the voting rights,
if any, of such series;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(c)&#160;&#160;&#160;the
rate of dividends payable on such series, the time or times when such dividends will be payable, the preference to, or any relation
to, the payment of dividends to any other class or series of stock and whether the dividends will be cumulative or non-cumulative;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(d)&#160;&#160;&#160;whether
there shall be a sinking or similar fund for the purchase of shares of such series and, if so, the terms and provisions that shall
govern such fund;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">(e)&#160;&#160;&#160;the rights of the holders
of shares of such series upon the liquidation, dissolution or winding up of the Corporation;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(f)&#160;&#160;&#160;&#160;&#160;the
rights, if any, of holders of shares of such series to convert such shares into, or to exchange such shares for, shares of any
other class or classes or any other series of the same or of any other class or classes of Equity Shares, the price or prices or
rate or rates of conversion or exchange, with such adjustments thereto as shall be provided, at which such shares shall be convertible
or exchangeable, whether such rights of conversion or exchange shall be exercisable at the option of the holder of the shares or
the Corporation (or both) or upon the happening of a specified event, and any other terms or conditions of such conversion or exchange;
and</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(g)&#160;&#160;&#160;any
other preferences, powers and relative participating, optional or other special rights and qualifications, limitations or restrictions
of shares of such series.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
4.03&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Preemptive Rights</B>.&#160;&#160;No holder of Equity Shares shall, in its
capacity as such a holder, have any preemptive or other right to purchase or subscribe for any Equity Shares or any other security
of the Corporation that the Corporation may issue or sell other than such right, if any, as the Board of Directors, in its discretion,
may determine.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
V</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>DEFINING,
LIMITING AND REGULATING POWERS OF THE CORPORATION,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>THE
BOARD OF DIRECTORS AND THE STOCKHOLDERS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; General</B>.&#160;&#160;Subject to the express limitations set forth in these
Articles or in the Bylaws, the business and affairs of the Corporation shall be managed by or under the direction of the Board
of Directors.</P>





<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.02&#160;&#160;&#160;&#160;&#160;&#160;&#160; Business Combinations</B>.&#160;&#160;The affirmative vote of the holders of not
less than 80% of the outstanding shares of Voting Stock of the Corporation shall be required for the approval or authorization
of any Business Combination. However, such 80% voting requirement shall not be applicable if: (1) the Board of Directors by unanimous
vote or written consent shall have expressly approved in advance the acquisition of outstanding shares of Voting Stock of the Corporation
that caused the Related Person to become a Related Person or shall have approved the Business Combination prior to the Related
Person involved in the Business Combination having become a Related Person; or (2)&#160;the Business Combination is solely between
the Corporation and another corporation, 100% of the Voting Stock of which is owned directly or indirectly by the Corporation.
For purposes of this Section 5.02:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-left: 36pt">(1)&#160;&#160;&#160;The
term &#8220;<B>Business Combination</B>&#8221; shall mean (a) any merger or consolidation of the Corporation<B>&#160;</B>with or
into a Related Person, (b) any sale, lease, exchange, transfer or other disposition, including without limitation a mortgage or
any other security device, of all or any Substantial Part of the assets of the Corporation<B>&#160;</B>(including without limitation
any voting securities of a subsidiary) to a Related Person, (c) any merger or consolidation of a Related Person with or into the
Corporation, (d) any sale, lease, exchange, transfer or other disposition of all or any Substantial Part of the assets of a Related
Person to the Corporation, (e) the issuance of any securities (other than by way of pro rata distribution to all Stockholders)
of the Corporation<B>&#160;</B>to a Related Person, and (f) any agreement, contract or other arrangement providing for any of the
transactions described in this definition of Business Combination.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(2)&#160;&#160;&#160;The
term &#8220;<B>Related Person</B>&#8221; shall mean and include any individual, corporation, partnership or other person or entity
that, together with its Affiliates and &#8220;Associates&#8221; (as defined in Rule 12b-2 under the Exchange Act ), &#8220;Beneficially
Owns&#8221; (as defined in Rule 13d-3 under the Exchange Act ) in the aggregate 10% or more of the outstanding Voting Stock of
the Corporation, and any Affiliate or Associate of the Corporation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
The term &#8220;<B>Substantial Part</B>&#8221; shall mean more than 10% of the book value of the total assets of the Corporation
as of the end of its most recent fiscal year ending prior to the time the determination is being made.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
For purposes of this Section 5.02, without limitation, any Common Shares that any Related Person has the right to acquire pursuant
to any agreement, or upon exercise of conversion rights, warrants or options, or otherwise, shall be deemed to be Beneficially
Owned by the Related Person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
The term &#8220;<B>Voting Stock</B>&#8221; shall mean the outstanding shares of capital stock of an entity entitled to vote generally
in such entity&#8217;s election of its board of directors or similar governing body. In a vote required by or provided for in this
Section 5.02, each share of the Corporation&#8217;s Voting Stock shall have the number of votes granted to it generally in the
election of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.03&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Board of Directors.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(a)&#160;&#160;&#160;The
number of Directors constituting the whole Board of Directors as of the effective date of these Articles shall be six (6), which
number may be increased or decreased from time to time in such manner as may be provided in the Bylaws; provided, however, that
the number of Directors constituting the full Board of Directors shall not be less than five (5) nor more than thirteen (13), subject,
at all times, to the rights of the holders of any class of Preferred Stock to elect Directors in certain circumstances specified
pursuant to the express terms of such Preferred Stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(b)&#160;&#160;&#160;The
Board of Directors shall be classified into three (3) groups of Directors.&#160;&#160;Each Director shall serve for successive
terms ending at the Annual Meeting of Stockholders held during the third (3<FONT STYLE="vertical-align: text-top">rd</FONT>) year
after election and until his or her successor shall have been duly elected and shall have qualified.&#160;&#160;The names of the
current Directors who shall serve until the next Annual Meeting of Stockholders in the year when their respective term expires
and until their successors are duly elected and qualify are as follows:</P>



<P STYLE="text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C. Taylor Pickett</FONT></TD>
    <TD STYLE="text-align: left; width: 50%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Term to expire in 2011)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Harold J. Kloosterman</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Term to expire in 2011)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bernard J. Korman</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Term to expire in 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Thomas F. Franke</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Term to expire in 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Edward Lowenthal</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Term to expire in 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stephen D. Plavin</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Term to expire in 2013)</FONT></TD></TR>
</TABLE>


<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.04&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Restrictions on Ownership and Transfer</B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>Definitions</U>. For purposes of Section 5.04 through Section 5.08, the following terms shall have the following meanings:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Acquire</B>&#8221;
means the acquisition of Beneficial Ownership or Constructive Ownership of Equity Shares by any means, including, without limitation,
the exercise of any rights under any option, warrant, convertible security, pledge or other security interest or similar right
to acquire Equity Shares, but shall not include the acquisition of any such rights unless, as a result, the acquirer would be considered
a Beneficial Owner or Constructive Owner. The terms &#8220;<B>Acquires</B>&#8221; and &#8220;<B>Acquisition</B>&#8221; shall have
correlative meanings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Beneficial
Ownership</B>&#8221; means ownership of Equity Shares by a Person whether the interest in such Equity Shares is held directly or
indirectly (including by a nominee) and shall include interests that would be treated as owned through the application of Section&#160;544
of the Code, as modified by Section&#160;856(h)(1)(B) and 856(h)(3) of the Code. The terms &#8220;<B>Beneficial Owner</B>,&#8221;
 &#8220;<B>Beneficially Owns</B>,&#8221; &#8220;<B>Beneficially Own</B>&#8221; and &#8220;<B>Beneficially Owned</B>&#8221; shall
have correlative meanings. For purposes of determining the percentage ownership of Common Shares by any Person, Common Shares that
may be acquired upon conversion, exchange or exercise of any securities of the Corporation directly or constructively held by such
Person shall be deemed to be outstanding prior to conversion, exchange or exercise, but not Common Shares issuable with respect
to the conversion, exchange or exercise of securities of the Corporation held by other Persons.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Beneficiary</B>&#8221;
means a beneficiary of the Trust as determined pursuant to Section 5.05(e)&#160;hereof.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Business
Day</B>&#8221; means any day other than a Saturday or Sunday that is neither a legal holiday nor a day on which banking institutions
in the State of New York are authorized or required by law or regulation or executive order to close.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Common
Share Ownership Limit</B>&#8221; means, with respect to any class of Common Shares, ownership of 9.8% or more (by value or number
of shares, whichever is more restrictive) of the outstanding Common Shares, subject to adjustment pursuant to Section 5.04(j) and
to any other limitations contained in this Section 5.04.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Constructive
Ownership</B>&#8221; means ownership of Equity Shares by a Person who could be treated as an owner of such Equity Shares, either
actually or constructively, directly or indirectly (including by a nominee), through the application of Section&#160;318(a) of
the Code, as modified by Section&#160;856(d)(5)&#160;thereof. The terms &#8220;<B>Constructive Owner</B>,&#8221; &#8220;<B>Constructively
Owns</B>,&#8221; &#8220;<B>Constructively Own</B>&#8221; and &#8220;<B>Constructively Owned</B>&#8221; shall have correlative meanings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Equity
Share Ownership Limit</B>&#8221; means, with respect to the Corporation&#8217;s Equity Shares, either (i) the Common Share Ownership
Limit, (ii)&#160;the Preferred Share Ownership Limit, or (iii) ownership of a combination of any class of Common Shares and/or
Preferred Shares of 9.8% or more by value or total number (whichever is more restrictive) of the outstanding Equity Shares, subject
to adjustment pursuant to Section 5.04(j) and to any other limitations contained in this Section 5.04.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Excepted
Holder</B>&#8221; means a Person for whom an Excepted Holder Limit is created by these Articles or by the Board of Directors pursuant
to Section 5.04(i).</P>




<P>&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Excepted
Holder Limit</B>&#8221; means, provided that the affected Excepted Holder agrees to comply with the requirements established by
these Articles or by the Board of Directors pursuant to Section 5.04(i) and subject to adjustment pursuant to Section 5.04(i),
the percentage limit established for an Excepted Holder by these Articles or by the Board of Directors pursuant to Section 5.04(i).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>IRS</B>&#8221;
means the Internal Revenue Service of the United States.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Market
Price</B>&#8221; means, on any date, with respect to any class or series of outstanding Equity Shares, the average of the Closing
Price for such Equity Shares for the five (5)&#160;consecutive Trading Days ending on such date. The &#8220;<B>Closing Price</B>&#8221;
on any date means the last sale price for such Equity Shares, regular way, or, in case no such sale takes place on such day, the
average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction
reporting system with respect to securities listed or admitted to trading on the NYSE or, if the Equity Shares are not listed or
admitted to trading on the NYSE, as reported in the principal consolidated transaction reporting system with respect to securities
listed on the principal national securities exchange on which the Equity Shares are listed or admitted to trading or, if the Equity
Shares are not listed or admitted to trading on any national securities exchange, the last quoted price, or if not so quoted, the
average of the high bid and low asked prices in the over-the-counter market, as reported by The NASDAQ Stock Market, Inc. (NASDAQ)
or, if such system is no longer in use, the principal other automated quotations system that may then be in use or, if the Equity
Shares are not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional
market maker making a market in the Equity Shares selected by the Board of Directors, or, if no such market maker exists, as determined
in good faith by the Board of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Preferred
Share Ownership Limit</B>&#8221; means, with respect to the Preferred Shares, ownership of 9.8% or more (by value or number of
shares, whichever is more restrictive) of an outstanding class or series of Preferred Shares, subject to adjustment pursuant to
Section 5.04(j) and to any other limitations contained in Section 5.04.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Purported
Beneficial Holder</B>&#8221; means, with respect to any purported Transfer or Acquisition or other event or transaction that results
in Shares-in-Trust, the Person for whom the applicable Purported Record Holder held the Equity Shares that were, pursuant to Section
5.04(c), automatically converted to Shares-in-Trust upon the occurrence of such event or transaction. The Purported Beneficial
Holder and the Purported Record Holder may be the same Person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Purported
Beneficial Transferee</B>&#8221; means, with respect to any purported Transfer or Acquisition or other event or transaction that
results in Shares-in-Trust, the purported beneficial transferee for whom the Purported Record Transferee would have acquired Equity
Shares if such Transfer or Acquisition that results in Shares-in-Trust had been valid under Section 5.04(b). The Purported Beneficial
Transferee and the Purported Record Transferee may be the same Person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Purported
Record Holder</B>&#8221; means, with respect to any purported Transfer or Acquisition or other event or transaction that results
in Shares-in-Trust, the record holder of the Equity Shares that were, pursuant to Section 5.04(c), automatically converted to Shares-in-Trust
upon the occurrence of such an event or transaction. The Purported Record Holder and the Purported Beneficial Holder may be the
same Person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Purported
Record Transferee</B>&#8221; means, with respect to any purported Transfer or Acquisition or other event or transaction that results
in Shares-in-Trust, the record holder of the Equity Shares if such Transfer or Acquisition that results in Shares-in-Trust had
been valid under Section 5.04(b). The Purported Record Transferee and the Purported Beneficial Transferee may be the same Person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Restriction
Termination Date</B>&#8221; means the first day after the date on which the Board of Directors determines, in accordance with Section
5.04(l), that it is no longer in the best interests of the Corporation to attempt or continue to qualify as a REIT, and all actions
necessary to terminate the Corporation&#8217;s status as a REIT hereunder have been taken, or that compliance with the restrictions
and limitations on Beneficial Ownership, Constructive Ownership and Transfers set forth in these Articles is no longer required
for the Corporation to qualify as a REIT.</P>





<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Shares-in-Trust</B>&#8221;
means those shares into which Equity Shares are automatically converted as a result of a purported Transfer, Acquisition or other
event or transaction, as described in Section 5.04(c).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Trading
Day</B>&#8221; means (i)&#160;a day on which the principal national securities exchange on which the affected class or series of
Equity Shares is listed or admitted to trading is open for the transaction of business, or (ii)&#160;if the affected class or series
of Equity Shares is not so listed or admitted to trading, any Business Day.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Transfer</B>&#8221;
means any sale, transfer, gift, hypothecation, assignment, devise or other disposition of a direct or indirect interest in Equity
Shares or the right to vote or receive dividends on Equity Shares, including without limitation (i)&#160;the granting of any option
(including any option to acquire an option or any series of such options)&#160;or entering into any agreement for the sale, transfer
or other disposition of Equity Shares or the right to vote or receive dividends on Equity Shares or (ii)&#160;the sale, transfer,
assignment or other disposition of any securities or rights convertible into or exchangeable for Equity Shares, whether voluntary
or involuntary, of record, constructively or beneficially, and whether by operation of law or otherwise. The terms &#8220;<B>Transfers</B>,&#8221;
 &#8220;<B>Transferred</B>&#8221; and &#8220;<B>Transferable</B>&#8221; shall have correlative meanings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Trust</B>&#8221;
means a trust created pursuant to Section 5.05(a) hereof.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 108pt; margin-right: 0; margin-left: 0">&#8220;<B>Trustee</B>&#8221;
means the trustee of the Trust, as appointed by the Corporation or any successor trustee thereof, which Trustee shall not be an
Affiliate of the Corporation or of the Purported Record Holder, the Purported Beneficial Holder, the Purported Record Transferee
or the Purported Beneficial Transferee.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(b)&#160;&#160;&#160;<U>Ownership
and Transfer Limitations.</U>&#160;&#160;At all times prior to the Restriction Termination Date, notwithstanding any other provision
of these Articles, but subject to the exercise of the Board&#8217;s discretion to establish an Excepted Holder Limit under the
provisions of Section 5.04(i), and subject to Section 5.06,</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
no Person, other than an Excepted Holder, shall Beneficially Own or Constructively Own Equity Shares in excess of the Equity Share
Ownership Limit, and no Excepted Holder shall Beneficially Own or Constructively Own Equity Shares in excess of the Excepted Holder
Limit for such Excepted Holder;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
no Person shall Beneficially Own or Constructively Own Equity Shares to the extent that such Beneficial or Constructive Ownership
would cause the Corporation to fail to qualify as a REIT by reason of being &#8220;closely held&#8221; within the meaning of Section
856(h) of the Code (without regard to whether the ownership interest is held during the last half of a taxable year); and</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no
Person shall Beneficially Own or Constructively Own Equity Shares that would cause the Corporation to otherwise fail to qualify
as a REIT (including, but not limited to, Beneficial or Constructive Ownership that would result in the Corporation owning (actually
or Constructively) an interest in a tenant that is described in Section 856(d)(2)(B) of the Code if the income derived by the Corporation
from such tenant would cause the Corporation to fail to satisfy any of the gross income requirements of Section 856(c) of the Code).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin-right: 0; margin-left: 0">Subject
to Section 5.06 and notwithstanding any other provisions of these Articles, at all times prior to the Restriction Termination Date,
any Transfer, Acquisition or other event or transaction that, if effective, would result in the Equity Shares of the Corporation
being beneficially owned by less than 100 Persons (determined without reference to any rules of attribution) shall be void ab initio,
and the intended transferee shall acquire no rights in such Equity Shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(c)&#160;&#160;&#160;<U>Shares-in-Trust</U>.
If, at any time prior to the Restriction Termination Date, any Transfer, Acquisition or other event or transaction that, if effective,
would result in any Person Beneficially Owning or Constructively Owning Equity Shares in violation of Section 5.04(b)(i) or (iii)
above,</P>




<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
then that number of Equity Shares that otherwise would cause such Person to violate Section 5.04(b)(i) or (iii) above (rounded
up to the nearest whole share) shall be automatically converted into an equal number of Shares-in-Trust having terms, rights, restrictions
and qualifications identical thereto (except to the extent that Section 5.04 or Section 5.05 requires different terms), effective
as of the close of business on the Business Day next preceding the date of such Transfer, Acquisition or other event or transaction,
and such Purported Beneficial Transferee shall thereafter have no rights in such Equity Shares, and</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
if, for any reason, the conversion into Shares-in-Trust described in subsection (c)(i) above is not automatically effective as
provided therein to prevent any Person from Beneficially Owning or Constructively Owning Equity Shares in violation of Section
5.04(b)(i) or (iii) above, then the Transfer, Acquisition or other event or transaction with respect to that number of Equity Shares
that otherwise would cause any Person to violate Section 5.04(b)(i) or (iii) shall, subject to Section 5.06, be void ab initio,
and the Purported Beneficial Transferee shall acquire no rights in such Equity Shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(d)&#160;&#160;&#160;<U>Remedies
for Breach</U>. If the Board of Directors, a duly authorized committee thereof or other designee, if permitted by the MGCL, shall
at any time determine in good faith that a purported Transfer, Acquisition or other event or transaction has taken place in violation
of Section 5.04(b) or that a Person intends to Acquire or has attempted to Acquire Beneficial Ownership or Constructive Ownership
of any Equity Shares in violation of this Section 5.04 (whether or not such violation is intended), the Board of Directors or a
committee thereof or other designee shall take such action as it deems advisable to refuse to give effect to or to prevent such
Transfer, Acquisition or other event or transaction from occurring or otherwise being effective, including, but not limited to,
causing the Corporation to redeem Equity Shares, refusing to give effect thereto on the books of the Corporation or instituting
injunctive proceedings with respect thereto; provided, however, that any Transfer, Acquisition, event or transaction in violation
of Section 5.04(b) shall be void ab initio or automatically shall result in the conversion described in Section 5.04(c), as applicable,
irrespective of any action (or inaction)&#160;by the Board of Directors or its designee.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(e)&#160;&#160;&#160;<U>Notice
of Restricted Transfer</U>. Any Person who Acquires or attempts to Acquire Beneficial Ownership or Constructive Ownership of Equity
Shares that will or may violate Section 5.04(b) and any Person who Beneficially Owns or Constructively Owns Shares-in-Trust as
a transferee of Equity Shares resulting in a conversion to Shares-in-Trust, pursuant to Section 5.04(c) or otherwise, shall immediately
give written notice to the Corporation, or, in the event of a proposed or attempted Transfer, Acquisition, or purported change
in Beneficial Ownership or Constructive Ownership, shall give at least fifteen (15)&#160;days prior written notice to the Corporation,
of such event and shall promptly provide to the Corporation such other information as the Corporation, in its sole discretion,
may request.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">(f)&#160;&#160;&#160;<U>Owners Required
to Provide Information</U>. At all times prior to the Restriction Termination Date:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Every Beneficial Owner or Constructive Owner of more than five percent (5%) (or such lower percentages as determined pursuant to
regulations under the Code or as may be requested by the Board of Directors, in its sole discretion), of the outstanding Equity
Shares of any class or series shall annually, no later than thirty (30)&#160;days after the end of each taxable year, give written
notice to the Corporation stating (1)&#160;the name and address of such Beneficial Owner or Constructive Owner; (2)&#160;the number
of shares of each class or series of Equity Shares Beneficially Owned or Constructively Owned; and (3)&#160;a description of how
such shares are held. Each such Beneficial Owner or Constructive Owner promptly shall provide to the Corporation such additional
information as the Corporation, in its sole discretion, may request to determine the effect, if any, of such Beneficial Ownership
or Constructive Ownership on the Corporation&#8217;s status as a REIT and to ensure compliance with the Common Share Ownership
Limit or Preferred Share Ownership Limit and other restrictions set forth in these Articles.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Each Person who is a Beneficial Owner or Constructive Owner of Equity Shares and each Person (including the Stockholder of record)&#160;who
is holding Equity Shares for a Beneficial Owner or Constructive Owner promptly shall provide to the Corporation such information
as the Corporation, in its sole discretion, may request to determine the Corporation&#8217;s status as a REIT, to comply with the
requirements of any taxing authority or other governmental agency, or to determine any such compliance or to ensure compliance
with the Equity Share Ownership Limits and other restrictions set forth in these Articles.<BR>
</P>

<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>




<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(g)&#160;&#160;&#160;<U>Remedies
Not Limited</U>. Subject to Section 5.06 and Section 5.04(l), nothing contained in this ARTICLE V shall limit the scope or application
of the provisions of this Section 5.04, the ability of the Corporation to implement or enforce compliance with the terms of this
Section 5.04 or the authority of the Board of Directors to take any such other action or actions as it may deem necessary or advisable
to protect the Corporation and the interests of its Stockholders by preservation of the Corporation&#8217;s status as a REIT and
to ensure compliance with the Equity Ownership Limit for any class or series (or combination thereof) of Equity Shares and other
restrictions set forth in this Section 5.04, including, without limitation, refusal to give effect to a transaction on the books
of the Corporation.&#160;&#160;For the avoidance of doubt, the Corporation is specifically authorized to seek equitable relief,
including injunctive relief, to enforce the provisions of Section 5.04 and Section 5.05.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(h)&#160;&#160;&#160;<U>Ambiguity</U>.
In the case of an ambiguity in the application of any of the provisions of this Section 5.04, including any definition contained
in Section 5.02, Section 5.04(a) or Section 7.01, the Board of Directors shall have the power and authority, in its sole discretion,
to determine the application of the provisions of this Section 5.04 with respect to any situation based on the facts known to it.
In the event Section 5.04 or Section 5.05 requires an action by the Board of Directors and these Articles fail to provide specific
guidance with respect to such action, the Board of Directors shall have the power to determine the action to be taken so long as
such action is not contrary to the purposes and intents set forth in these Articles. Absent a decision to the contrary by the Board
of Directors (which the Board of Directors may make in its sole and absolute discretion), if a Person would have (but for the remedies
set forth in Section 5.04)&#160;acquired Beneficial Ownership or Constructive Ownership of Equity Shares in violation of Section
5.04, such remedies (as applicable)&#160;shall apply first to the Equity Shares that, but for such remedies, would have been actually
owned by such Person, and second to Equity Shares that, but for such remedies, would have been Beneficially Owned or Constructively
Owned (but not actually owned) by such Person, pro rata among the Persons who actually own such Equity Shares based upon the relative
number of the Equity Shares held by each such Person.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(i)&#160;&#160;&#160;<U>Waivers
by Board</U>. Upon notice of an Acquisition or Transfer or a proposed Acquisition or Transfer that results or would result in the
intended transferee having Beneficial Ownership of Equity Shares in excess of the Equity Share Ownership Limit, the Board of Directors
may, prospectively or retroactively, upon receipt of evidence that the Board of Directors deems to be satisfactory, in its sole
discretion, determine that such Acquisition or Transfer does not or will not violate the &#8220;closely held&#8221; provisions
of Section&#160;856(h)&#160;of the Code or otherwise cause the Corporation to fail to qualify as a REIT, create an Excepted Holder
Limit with respect to such transferee upon such conditions as the Board of Directors may determine, in its sole discretion.&#160;&#160;Subject
to Sections 5.04(b)(ii) and (iii), and without any action by the Board of Directors pursuant to this Section 5.04(i) or any other
provisions of these Articles, an underwriter that participates in a public offering or private placement of Equity Shares, or Person
acting in a similar capacity with respect to a financing involving Equity Shares, may Beneficially Own or Constructively Own Equity
Shares in excess of the Equity Share Ownership Limit, but only to the extent necessary to facilitate such public offering, private
placement or similar financing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(j)&#160;&#160;&#160;<U>Increase
in Common or Preferred Share Ownership Limit</U>. Subject to the limitations contained in Section 5.04(k), the Board of Directors
may from time to time increase the Equity Share Ownership Limit (or separately increase the Common Share Ownership Limit or the
Preferred Share Ownership Limit) for one or more Persons and/or decrease the Equity Share Ownership Limit (or separately decrease
the Common Share Ownership Limit or the Preferred Share Ownership Limit) for one or more Persons; provided, however, that a decrease
in Equity Share Ownership Limit (or separate decrease in Common Share Ownership Limit or Preferred Share Ownership Limit) will
not be effective for any Person whose percentage ownership of Equity Shares is in excess of such decreased Equity Share Ownership
Limit (or separately decreased Common Share Ownership Limit or Preferred Share Ownership Limit), as appropriate, until such time
as such Person&#8217;s percentage of the subject Equity Shares equals or falls below the decreased Equity Share Ownership Limit
(or separately decreased Common Share Ownership Limit or Preferred Share Ownership Limit), but until such time as such Person&#8217;s
percentage of the subject Equity Shares falls below such decreased Equity Share Ownership Limit (or separately decreased Common
Share Ownership Limit or Preferred Share Ownership Limit), any further acquisition of Equity Shares will be in violation of the
Equity Share Ownership Limit (including any separate Common Share Ownership Limit or Preferred Share Ownership Limit); and provided
further, that the increased Equity Share Ownership Limit (or separately increased Common Share Ownership Limit or Preferred Share
Ownership Limit) being granted to one or more new Persons does not or will not violate the &#8220;closely held&#8221; provisions
of Section 856(h) of the Code or otherwise cause the Corporation to fail to qualify as a REIT.&#160;&#160;Any decreases in the
Equity Share Ownership Limits (or separate decreases in Common Share Ownership Limits or Preferred Share Ownership Limits) generally
shall be made to ensure the Company&#8217;s continued status as a REIT, as determined by the Board of Directors in its sole discretion.</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">(k)&#160;&#160;&#160;<U>Limitations on Modifications</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
The Equity Share Ownership Limit (including the Common Share Ownership Limit or the Preferred Share Ownership Limit) for a class
or series of Equity Shares may not be increased and no additional Excepted Holder Limitations may be created if, after giving effect
to such increase or creation, the Corporation would be &#8220;closely held&#8221; within the meaning of Section 856(h) of the Code.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Prior to any granting of or modification to the Equity Share Ownership Limit (including the Common Share Ownership Limit or the
Preferred Share Ownership Limit) for any Person, whether or not an Excepted Holder, the Board of Directors may, in its sole and
absolute discretion, require such opinions of counsel, IRS ruling, affidavits, undertakings or agreements as it may deem necessary,
advisable or prudent, in each case in form and substance satisfactory to the Board, to determine or ensure the Corporation&#8217;s
status as a REIT; provided, however that the Board of Directors shall not be obligated to require any such favorable ruling, opinion,
affidavit, undertaking or agreement in order to create an Excepted Holder Limit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(l)&#160;&#160;&#160;<U>REIT
Qualification &#8211; Board Authority</U>.&#160;&#160;The Board of Directors shall have the authority and shall use its best efforts
to cause the Corporation to qualify for federal income tax treatment as a REIT.&#160;&#160;Notwithstanding any other provision
of these Articles, if the Board of Directors shall at any time determine that it is no longer in the best interests of the Corporation
to continue to be qualified as a REIT, the Board of Directors may revoke or otherwise terminate the Corporation&#8217;s REIT election
pursuant to Section 856(g) of the Code.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.05&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares-In-Trust.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(a)&#160;&#160;&#160;<U>Ownership
in Trust</U>. Upon any purported Transfer or Acquisition or other event or transaction described in Section 5.04(b) that results
in Shares-in-Trust pursuant to Section 5.04(c), such Shares-in-Trust shall be deemed to have been Transferred to a Trust for the
exclusive benefit of the Beneficiary. Shares-in-Trust so held in trust shall be issued and outstanding Equity Shares of the Corporation.
The Purported Record Transferee or Purported Record Holder shall have no rights in such Shares-in-Trust except as specifically
provided in this Section 5.05.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(b)&#160;&#160;&#160;<U>Distribution
Rights</U>. Shares-in-Trust shall be entitled to the same rights and privileges as all other Equity Shares of the same class or
series. The Trustee will receive all dividends and distributions on the Shares-in-Trust and will hold such dividends and distributions
in trust for the benefit of the Beneficiary. Any dividend or distribution with a record date on or after the date that Equity Shares
have been converted to Shares-in-Trust paid on such Equity Shares to the Purported Record Transferee or to the Purported Record
Holder shall be repaid to the Trust, and any such dividend or distribution declared on such Equity Shares but unpaid shall be paid
to the Trust, in each case for the benefit of the Beneficiary. The Corporation shall take all measures that it determines are reasonably
necessary to recover the amount of any such dividend or distribution paid to the Purported Record Transferee or Purported Record
Holder, including, if necessary, withholding any portion of future dividends or distributions payable on Equity Shares Beneficially
Owned or Constructively Owned by such Persons and, as soon as reasonably practicable following the Corporation&#8217;s receipt
or withholding thereof, paying over to the Trust for the benefit of the Beneficiary the dividends or distributions so received
or withheld, as the case may be.</P>

<P STYLE="text-indent: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(c)&#160;&#160;&#160;<U>Rights
Upon Liquidation</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up, or any other similar
distribution of the assets of the Corporation, each holder of Shares-in-Trust resulting from the conversion of Equity Shares of
any specified class or series shall be entitled to receive, ratably with each other holder of Shares-in-Trust resulting from the
conversion of Equity Shares of such class or series together with each holder of Equity Shares of such class or series, that portion
of the remaining assets of the Corporation, as are due to holders of Preferred Shares of such class or series or available for
distribution to the holders of such class of Common Shares, as applicable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin-right: 0; margin-left: 0">The
Trustee shall distribute to the Purported Record Transferee or Purported Record Holder the amounts received upon such liquidation,
dissolution, winding up or distribution, provided that the Purported Record Transferee or Purported Record Holder shall not be
entitled to receive amounts pursuant to this Section 5.05(c)&#160;in excess of the price per share in the transaction that created
such Shares-in-Trust (or, in the case of a gift or devise, the Market Price per share on the date of such Transfer). Any remaining
amounts shall be distributed to the Beneficiary.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-left: 0">(d)&#160;&#160;&#160;<U>Voting
Rights</U>. The Trustee shall be entitled to vote the Shares-in-Trust on any matters on which holders of Equity Shares of the same
class or series are entitled to vote (except as required otherwise by the MGCL). Any vote taken with respect to Equity Shares that
have been converted into Shares-In-Trust prior to the discovery by the Corporation that such Equity Shares have been converted
into Shares-in-Trust shall, subject to applicable law, be rescinded and be void ab initio and be recast by the Trustee, in its
sole and absolute discretion; provided that if the Corporation has already taken irreversible corporate action based on such vote,
then such vote shall not be rescinded and the Trustee shall not have the authority to recast such vote. The Purported Record Transferee
or Purported Record Holder shall be deemed to have given, as of the date of the conversion of such Equity Shares into Shares-in-Trust
pursuant to Section 5.04(c), an irrevocable proxy to the Trustee to vote, in accordance with these Articles, the Shares-in-Trust
in the manner in which the Trustee, in its sole and absolute discretion, desires.&#160;&#160;Notwithstanding the provisions of
Section 5.04 or Section 5.05, until the Corporation has received notification that the Equity Shares have been converted into Shares-in-Trust,
the Corporation shall be entitled to rely on its share transfer and other Stockholder records for purposes of preparing lists of
Stockholders entitled to vote at meetings, determining the validity and authority of proxies and otherwise conducting votes of
Stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 72pt; margin-left: 0">(e)&#160;&#160;&#160;<U>Restrictions on
Transfer; Designation of Beneficiary; Sales of Shares-In-Trust</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(i)&#160;&#160;&#160;Except
as otherwise described in this Section 5.05(e), Shares-in-Trust shall not be transferable. The Beneficiary shall be one or more
charitable organizations described in Code Section 501(c)(3) (but not including any private foundation as defined in Code Section
509(a)), Code Section 170(b)(1)(A) or Code Section 170(c)(2) named by the Corporation within five (5) days after the Trust is established.
However, for purposes of sales by the Trustee as set forth in this Section 5.05(e), the Trustee shall designate a permitted transferee
of the Equity Shares represented by such Shares-in-Trust provided that the transferee (1)&#160;purchases such Equity Shares for
valuable consideration and (2) acquires such Equity Shares without such acquisition resulting in another automatic conversion of
Equity Shares into Shares-in-Trust. If the Corporation does not purchase the Shares-in-Trust pursuant to this Section 5.05(e),
the Trustee shall (A) sell that number of Equity Shares represented by such Shares-in-Trust to the permitted transferee described
above, (B) cause to be recorded on the books of the Corporation that the permitted transferee is the holder of record of such number
of Equity Shares, and (C) cause the Shares-in-Trust to be canceled.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(ii)&#160;&#160;&#160;In
the event of a sale by the Trustee of the Equity Shares represented by such Shares-in-Trust, the Purported Record Transferee or
Purported Record Holder shall receive from the Trustee a per share price equal to the lesser of (1)&#160;the price per share in
the transaction that created such Shares-in-Trust (or, in the case of a gift or devise, the Market Price per share on the date
of such transfer)&#160;and (2)&#160;the price per share received by the Trustee, provided that such price per share shall be net
of any commissions and other expenses of the sale. The proceeds shall be sent to such Person within five (5)&#160;Business Days
after the closing of such sale transaction.</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
All Shares-in-Trust will be deemed to have been offered for sale to the Corporation, or its designee, and the Corporation will
have the right to accept such offer for a period of twenty (20)&#160;days after the later of (1)&#160;the date of the purported
Transfer or Acquisition or other event or transaction described in Section 5.04(b) that results in such Shares-in-Trust, as set
forth in a notice received by the Corporation pursuant to Section 5.04(e) and (2)&#160;if no such notice is received by the Corporation,
the date the Corporation determines in good faith that a purported Transfer or Acquisition or other event or transaction described
in Section 5.04(b) that results in such Shares-in-Trust occurred. If the Corporation accepts the offer to purchase such Shares-in-Trust,
the purchase price per share shall be equal to the lesser of: (A)&#160;the price per share in the transaction that created such
Shares-in-Trust (or, in the case of a gift or devise, the Market Price at the time of such gift or devise),&#160;or (B)&#160;the
Market Price on the date the Corporation, or its designee, accepts such offer.&#160;&#160;The Corporation may reduce the amount
payable in connection with the purchase of such Shares-in-Trust by the amount of any dividends and other distributions that have
been paid to the Purported Record Transferee or the Purported Record Holder and are owed by the Purported Record Transferee or
the Purported Record Holder to the Trustee pursuant to Section 5.05(b).&#160;&#160;The Corporation may pay the amount of such reduction
to the Trustee for the benefit of the Beneficiary.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 36pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Any amounts received by the Trustee in excess of the amounts paid to the Purported Record Transferee or Purported Record Holder
shall be distributed to the Beneficiary.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.06</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Settlements</B>. Nothing in Section 5.04 or Section 5.05 shall
preclude the settlement of any transaction with respect to the Equity Shares entered into through the facilities of the NYSE or
other national securities exchange on which the Equity Shares are listed. The fact that the settlement of any transaction occurs
shall not negate the effect of any other provisions of Section 5.04 or Section 5.05, and any transferee in such a transaction shall
be subject to all of the provisions and limitations set forth in such Sections.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.07</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Severability</B>. If any provision of Section 5.04 or Section
5.05 or any application of any such provision is determined to be void, invalid or unenforceable by any court having jurisdiction
over the issue, the validity and enforceability of the remaining provisions of Section 5.04 or Section 5.05 shall not be affected
and other applications of such provision shall be affected only to the extent necessary to comply with the determination of such
court.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.08</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Waiver</B>. The Corporation shall have authority at any time to
waive the requirements that Shares-in-Trust be issued or be deemed outstanding in accordance with the provisions of Section 5.04
or Section 5.05 if the Corporation determines, based on an opinion of nationally recognized tax counsel, that the issuance of such
Shares-in-Trust or the fact that such Shares-in-Trust are deemed to be outstanding, would jeopardize the status of the Corporation
as a REIT.&#160;&#160;No delay or failure on the part of the Corporation or the Board of Directors in exercising any right under
this Section 5.08 shall operate as a waiver of any right of the Corporation or the Board of Directors, as the case may be, except
to the extent specifically waived in writing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.09</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Business Combination Statute; Control Share Acquisition Statute</B>.&#160;&#160;The
provisions of Subtitles 6 (Special Voting Requirements) and 7 (Voting Rights of Certain Control Shares) of Title 3 of the Corporations
and Associations Article of the MGCL shall not apply to the Corporation unless the Board of Directors elects by resolution to be
subject, in whole or in part, specifically, generally or generally by types, as to specifically identified or unidentified stockholders,
to the provisions of either or both Subtitles.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
5.10</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Vote Required</B>. Notwithstanding any provision of law requiring
any action to be taken or authorized by the affirmative vote of the holders of a greater proportion of the votes of all classes
or of any class of stock of the Corporation, such action shall be effective and valid if taken or authorized by the affirmative
vote of a majority of the total number of votes entitled to be cast thereon, except as otherwise provided by these Articles or
the Bylaws.</P>



<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
VI</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>LIABILITY
AND INDEMNIFICATION</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
6.01</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Limitation of Liability</B>.&#160;&#160;To the fullest extent
that limitations on the liability of directors and officers are permitted by the MGCL, no Director or officer of the Corporation
shall have any liability to the Corporation or the Stockholders for money or other damages. This limitation on liability applies
to events occurring at the time a person serves as a Director or officer of the Corporation whether or not such person is a Director
or officer at the time of any proceeding in which liability is asserted.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
6.02</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Indemnification</B>.&#160;&#160;The Corporation shall indemnify
and advance expenses to its Directors to the fullest extent that indemnification of, and advance of expenses to, directors is permitted
by the MGCL. The Corporation shall indemnify and advance expenses to its officers to the same extent as its Directors and to such
further extent as is consistent with applicable law. The Board of Directors may by Bylaw, resolution or agreement make further
provision for indemnification of Directors, officers, employees and agents to the fullest extent permitted by the MGCL.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
6.03</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Effect of Amendment</B>.&#160;&#160;No future amendment to these
Articles shall affect any right of any person under this ARTICLE VI based on any event, omission or proceeding occurring prior
to such amendment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>ARTICLE
VII</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>MISCELLANEOUS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
7.01</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Definitions</B>.&#160;&#160;As used in these Articles, the
following terms shall have the following meanings unless the context otherwise requires:</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Affiliate</B>&#8221;
or &#8220;<B>Affiliated</B>&#8221; means, as to a specified Person, any other Person that directly or indirectly through one or
more intermediaries controls, or is controlled by, or is under common control with, the Person specified.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Articles</B>&#8221;
means these Articles of Amendment and Restatement, as the same may be amended or supplemented from time to time.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Bylaws</B>&#8221;
means the bylaws of the Corporation, as the same are in effect and may be amended from time to time.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Code</B>&#8221;
means the Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto. Reference to any provision
of the Code means such provision as in effect from time to time, as the same may be amended, and any successor provision thereto,
as interpreted by any applicable regulations as in effect from time to time.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Common
Shares</B>&#8221; or<B> &#8220;Common Stock&#8221;</B> means the Corporation&#8217;s common stock, par value $.10 per share, which
may be issued from time to time in accordance with the terms of these Articles and applicable law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Directors</B>,&#8221;
 &#8220;<B>Board of Directors</B>&#8221; or &#8220;<B>Board</B>&#8221; means, collectively, the individuals appointed as Directors
of the Corporation pursuant to Section 5.03 of these Articles so long as they continue in office and all other individuals who
have been duly elected and qualify as Directors of the Corporation hereunder.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Equity
Shares</B>&#8221; means shares of capital stock of the Corporation of any class or series, including Common Shares and Preferred
Shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>&#8220;Exchange
Act&#8221;</B> means the Securities Exchange Act of 1934, as amended.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Individual</B>&#8221;
means an individual and shall also include any organization, trust, foundation and other entity that is considered or treated as
an individual for the purposes of Section&#160;542(a)(2) of the Code.</P>



<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>MGCL</B>&#8221;
means the Maryland General Corporation Law, as amended from time to time, or any successor statute thereto.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>NYSE</B>&#8221;
means the New York Stock Exchange, Inc.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Person</B>&#8221;
means an Individual, corporation, partnership, estate, trust, association, joint stock company or other entity, or any government
or any agency or political subdivision thereof, and also includes a group, as that term is used for purposes of Section&#160;13(d)(3)&#160;of
the Exchange Act.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Preferred
Shares</B>&#8221; or<B> &#8220;Preferred Stock&#8221;</B> means shares of the Corporation&#8217;s preferred stock, par value $1.00
per share, which may be issued in one or more classes or series in accordance with the terms of these Articles and applicable law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>REIT</B>&#8221;
means a &#8220;real estate investment trust&#8221; as defined pursuant to Sections&#160;856 through 860 of the Code.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">&#8220;<B>Stockholders</B>&#8221;
means the registered holders of the Equity Shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
7.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amendment.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 0">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
Corporation reserves the right from time to time to amend, alter or repeal any provision contained in these Articles in the manner
now or hereafter prescribed by statute and these Articles, including any amendment that alters the contract rights of any class
of outstanding stock as expressly set forth in these Articles, and all rights conferred on the Stockholders in these Articles are
subject to this reservation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 0">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding
any of the provisions of these Articles or the Bylaws of the Corporation (and not withstanding the fact that a lesser percentage
may be specified by law, these Articles or the Bylaws of the Corporation), the repeal or amendment of any provision of Section
5.02, Section 5.03, Section 5.04 or Section 5.05 shall be valid only if declared advisable by the Board of Directors and approved
by the affirmative vote of holders of not less than 80% of the total number of votes entitled to be cast thereon.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 72pt; margin-right: 0; margin-left: 0">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
Board of Directors may amend these Articles by a majority vote of the entire Board and without any action by the Stockholders to
the fullest extent so provided by the MGCL including, but not limited to, Section&#160;2-605 of the MGCL.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
7.03</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Governing Law</B>. These Articles are executed and delivered in
the State of Maryland with reference to the laws thereof, and the rights of all parties and the validity, construction and effect
of every provision of these Articles shall be subject to and construed in accordance with the laws of the State of Maryland without
regard to conflicts of laws provisions thereof.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>Section
7.04</B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Construction</B>. In these Articles, unless the context otherwise
requires, words used in the singular or in the plural include both the plural and singular, and words denoting any gender include
both genders. The title and headings of different parts are inserted for convenience and shall not affect the meaning, construction
or effect of these Articles.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>THIRD</B>:
These Articles have been advised by the Board of Directors and approved by the Stockholders of the Corporation as required by law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>FOURTH</B>:
The current address of the principal office of the Corporation in the State of Maryland and the name and address of the Corporation&#8217;s
current registered agent are as set forth in ARTICLE III of these Articles.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>FIFTH</B>:
The number of Directors of the Corporation and the names of those Directors currently in office are as set forth in Section 5.03
of these Articles.</P>



<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>SIXTH</B>:
The undersigned President acknowledges these Articles to be the corporate act of the Corporation and as to all matters or facts
required to be verified under oath, the undersigned President acknowledges that, to the best of his knowledge, information and
belief, these matters and facts are true in all material respects and that this statement is made under the penalties for perjury.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0"><B>IN
WITNESS WHEREOF</B>, Omega Healthcare Investors, Inc. has caused these Articles of Amendment and Restatement to be signed in its
name and on its behalf by its President, and attested by its Secretary, on this&#160;10th day of June, 2010.</P>







<P STYLE="text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OMEGA HEALTHCARE INVESTORS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 2px solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ C. Taylor Pickett</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C. Taylor Pickett, President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin-right: 0; margin-left: 0">ATTEST:</P>





<P STYLE="text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 2px solid; width: 21%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Daniel J. Booth</FONT></TD>
    <TD STYLE="width: 74%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Daniel J. Booth, Secretary</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"></P>

<P>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B><U>Omega
Healthcare Investors, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><B>Exhibit
A to Articles of Amendment and Restatement</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; margin-right: 0; margin-left: 0"><U>Series
D Preferred<BR>
</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">1.&#160;&#160;&#160;<B>Designation
and Number</B><I>.</I>&#160;&#160;&#160;&#160;A series of Preferred Stock, designated the &#8220;8.375% Series&#160;D Cumulative
Redeemable Preferred Stock&#8221; (the &#8220;<B>Series&#160;D Preferred Stock</B>&#8221;), is hereby established. The number of
shares of the Series&#160;D Preferred Stock shall be Four Million Seven Hundred Thirty-Nine Thousand Five Hundred (4,739,500).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">2.&#160;&#160;&#160;<B>Maturity</B><I>.</I>&#160;&#160;&#160;&#160;The
Series&#160;D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">3.&#160;&#160;&#160;<B>Rank</B><I>.</I>&#160;&#160;&#160;&#160;The
Series&#160;D Preferred Stock will, with respect to dividend rights and rights upon liquidation, dissolution or winding up of the
Company, rank (i)&#160;senior to all classes or series of Common Stock of the Company, and to all equity securities ranking junior
to the Series&#160;D Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or winding up of the
Company; (ii)&#160;on a parity with the Series&#160;A and Series&#160;B Preferred Stock and all other equity securities issued
by the Company the terms of which specifically provide that such equity securities rank on a parity with the Series&#160;D Preferred
Stock with respect to dividend rights or rights upon liquidation, dissolution or winding up of the Company; and (iii)&#160;junior
to all existing and future indebtedness of the Company. The term &#8220;equity securities&#8221; does not include convertible debt
securities, which will rank senior to the Series&#160;D Preferred Stock prior to conversion.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">4.&#160;&#160;&#160;<B>Dividends</B><I>.</I>&#160;&#160;&#160;&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(a)&#160;&#160;&#160;&#160;Holders
of shares of the Series&#160;D Preferred Stock are entitled to receive, when and as declared by the Board of Directors (or a duly
authorized committee thereof), out of funds legally available for the payment of dividends, preferential cumulative cash dividends
at the rate of 8.375% per annum of the Liquidation Preference (as defined below) per share (equivalent to a fixed annual amount
of $2.09375 per share). Dividends on the Series&#160;D Preferred Stock shall be cumulative from the date of original issue and
shall be payable in arrears for each period ended April&#160;30, July&#160;31, October&#160;31, and January&#160;31, on or before
the 15th day of May, August, November, February, of each year, or, if not a business day, the next succeeding business day (each,
a &#8220;<B>Dividend Payment Date</B>&#8221;). The first dividend will be paid on May&#160;17, 2004, with respect to the period
commencing on the date of issue and ending on April&#160;30, 2004. Any dividend payable on the Series&#160;D Preferred Stock for
any partial period will be computed on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable
to holders of record as they appear in the stock records of the Company at the close of business on the applicable record date,
which shall be the last day of the preceding calendar month prior to the applicable Dividend Payment Date or on such other date
designated by the Board of Directors of the Company that is not more than 30 nor less than 10&#160;days prior to such Dividend
Payment Date (each, a &#8220;<B>Dividend Record Date</B>&#8221;).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(b)&#160;&#160;&#160;&#160;No
dividends on shares of Series&#160;D Preferred Stock shall be declared by the Board of Directors or paid or set apart for payment
by the Company at such time as the terms and provisions of any agreement of the Company, including any agreement relating to its
indebtedness, prohibits such declaration, payment or setting apart for payment or provides that such declaration, payment or setting
apart for payment would constitute a breach thereof or a default thereunder, or if such declaration or payment shall be restricted
or prohibited by law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(c)&#160;&#160;&#160;&#160;Notwithstanding
the foregoing, dividends on the Series&#160;D Preferred Stock will accrue whether or not the Company has earnings, whether or not
there are funds legally available for the payment of such dividends and whether or not such dividends are declared and whether
or not such is prohibited by agreement. Accrued but unpaid dividends on the Series&#160;D Preferred Stock will not bear interest
and holders of the Series&#160;D Preferred Stock will not be entitled to any distributions in excess of full cumulative distributions
described above. Except as set forth in the next sentence, no dividends will be declared or paid or set apart for payment on any
capital stock of the Company or any other series of Preferred Stock ranking, as to dividends, on a parity with or junior to the
Series&#160;D Preferred Stock (other than a dividend in shares of the Company&#8217;s Common Stock or in shares of any other class
of stock ranking junior to the Series&#160;D Preferred Stock as to dividends and upon liquidation) for any period unless full cumulative
dividends have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof is set
apart for such payment on the Series&#160;D Preferred Stock for all past dividend periods and the then current dividend period.
When dividends are not paid in full (or a sum sufficient for such full payment is not so set apart) upon the Series&#160;D Preferred
Stock and the shares of any other series of Preferred Stock ranking on a parity as to dividends with the Series&#160;D Preferred
Stock, all dividends declared upon the Series&#160;D Preferred Stock and any other series of Preferred Stock ranking on a parity
as to dividends with the Series&#160;D Preferred Stock shall be declared pro rata so that the amount of dividends declared per
share of Series&#160;D Preferred Stock and such other series of Preferred Stock shall in all cases bear to each other the same
ratio that accrued dividends per share on the Series&#160;D Preferred Stock and such other series of Preferred Stock (which shall
not include any accrual in respect of unpaid dividends for prior dividend periods if such Preferred Stock does not have a cumulative
dividend) bear to each other.</P>



<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(d)&#160;&#160;&#160;&#160;Except
as provided in the immediately preceding paragraph, unless full cumulative dividends on the Series&#160;D Preferred Stock have
been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof is set apart for payment
for all past dividend periods and the then current dividend period, no dividends (other than in shares of Common Stock or other
shares of capital stock ranking junior to the Series&#160;D Preferred Stock as to dividends and upon liquidation) shall be declared
or paid or set aside for payment nor shall any other distribution be declared or made upon the Common Stock, or any other capital
stock of the Company ranking junior to or on a parity with the Series&#160;D Preferred Stock as to dividends or upon liquidation,
nor shall any shares of Common Stock, or any other shares of capital stock of the Company ranking junior to or on a parity with
the Series&#160;D Preferred Stock as to dividends or upon liquidation be redeemed, purchased or otherwise acquired for any consideration
(or any moneys be paid to or made available for a sinking fund for the redemption of any such shares) by the Company (except by
conversion into or exchange for other capital stock of the Company ranking junior to the Series&#160;D Preferred Stock as to dividends
and upon liquidation or redemptions for the purpose of preserving the Company&#8217;s qualification as a real estate investment
trust under the Internal Revenue Code of 1986, as amended). Holders of shares of the Series&#160;D Preferred Stock shall not be
entitled to any dividend, whether payable in cash, property or stock, in excess of full cumulative dividends on the Series&#160;D
Preferred Stock as provided above. Any dividend payment made on shares of the Series&#160;D Preferred Stock shall first be credited
against the earliest accrued but unpaid dividend due with respect to such shares which remains payable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">5.&#160;&#160;&#160;<I>
</I><B>Liquidation Preference</B><I>.</I>&#160;&#160;&#160;&#160;Upon any voluntary or involuntary liquidation, dissolution or
winding up of the affairs of the Company, the holders of shares of Series&#160;D Preferred Stock are entitled to be paid out of
the assets of the Company legally available for distribution to its shareholders a liquidation preference of $25 per share in cash
or property at its fair market value as determined by the board of directors (the &#8220;<B>Liquidation Preference</B>&#8221;),
plus an amount equal to any accrued and unpaid dividends to the date of payment, but without interest, before any distribution
of assets is made to holders of Common Stock or any other class or series of capital stock of the Company that ranks junior to
the Series&#160;D Preferred Stock as to liquidation rights. The Company will promptly provide to the holders of Series&#160;D Preferred
Stock written notice of any event triggering the right to receive such Liquidation Preference. After payment of the full amount
of the Liquidation Preference, plus any accrued and unpaid dividends to which they are entitled, the holders of Series&#160;D Preferred
Stock will have no right or claim to any of the remaining assets of the Company. The consolidation or merger of the Company with
or into any other corporation, trust or entity or of any other corporation with or into the Company, or the sale, lease or conveyance
of all or substantially all of the property or business of the Company, shall not be deemed to constitute a liquidation, dissolution
or winding up of the Company; provided that, in each case, effective provision is made in the organizational documents of the resulting
or surviving entity or otherwise for the rights of the holders of the Series&#160;D Preferred Stock to receive dividends and participate
in any distribution upon liquidation, dissolution or winding up of the affairs of such resulting or surviving entity in a manner
consistent with the provisions of this Article Third.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">In
determining whether a distribution (other than upon voluntary or involuntary liquidation) by dividend, redemption or other acquisition
of shares of stock of the Company or otherwise is permitted under the Maryland General Corporation Law (the &#8220;<B>MGCL</B>&#8221;),
no effect shall be given to amounts that would be needed if the Company would be dissolved at the time of the distribution, to
satisfy the preferential rights upon distribution of holders of shares of stock of the Company whose preferential rights upon distribution
are superior to those receiving the distribution.</P>



<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">6.&#160;&#160;&#160;<B>Redemption</B><I>.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(a)&#160;&#160;&#160;&#160;The
Series&#160;D Preferred Stock is not redeemable prior to February&#160;10, 2009 subject, however, to the provisions in paragraph&#160;(9)
of this Article Third. On and after February&#160;10, 2009, the Company, at its option, upon not less than 30 nor more than 60&#160;days&#8217;
written notice, may redeem shares of the Series&#160;D Preferred Stock, in whole or in part, at any time or from time to time,
for cash at a redemption price of $25 per share, plus all accrued and unpaid dividends thereon to the date fixed for redemption
(except with respect to any shares of Series&#160;D Preferred Stock that constitute Excess Shares (as defined in paragraph&#160;9
of this Article Third)) without interest. No shares of Series&#160;D Preferred Stock may be redeemed except with assets legally
available for the payment of the redemption price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">Holders
of Series&#160;D Preferred Stock to be redeemed shall surrender such Series&#160;D Preferred Stock at the place designated in such
notice and shall be entitled to the redemption price and any accrued and unpaid dividends payable upon such redemption following
such surrender. If notice of redemption of any shares of Series&#160;D Preferred Stock has been given and if the funds necessary
for such redemption have been set aside, separate and apart from other funds, by the Company in trust for the benefit of the holders
of any shares of Series&#160;D Preferred Stock so called for redemption, then from and after the redemption date dividends will
cease to accrue on such shares of Series&#160;D Preferred Stock, such shares of Series&#160;D Preferred Stock shall no longer be
deemed outstanding and all rights of the holders of such shares will terminate, except the right to receive the redemption price.
If less than all of the outstanding Series&#160;D Preferred Stock is to be redeemed, the Series&#160;D Preferred Stock to be redeemed
shall be selected pro rata (as nearly as may be practicable without creating fractional shares) or by any other equitable method
determined by the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(b)&#160;&#160;&#160;&#160;Unless
full cumulative dividends on all shares of Series&#160;D Preferred Stock shall have been or contemporaneously are declared and
paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods and the then
current dividend period, no shares of Series&#160;D Preferred Stock shall be redeemed unless all outstanding shares of Series&#160;D
Preferred Stock are simultaneously redeemed and the Company shall not purchase or otherwise acquire directly or indirectly any
shares of Series&#160;D Preferred Stock (except by exchange for capital stock of the Company ranking junior to the Series&#160;D
Preferred Stock as to dividends and upon liquidation); provided, however, that the foregoing shall not prevent the purchase by
the Company of any shares of Series&#160;D Preferred Stock that constitute Excess Shares in order to ensure that the Company continues
to meet the requirements for qualification as a real estate investment trust under the Internal Revenue Code, or the purchase or
acquisition of shares of Series&#160;D Preferred Stock pursuant to a purchase or exchange offer made on the same terms to holders
of all outstanding shares of Series&#160;D Preferred Stock. So long as no dividends are in arrears, the Company shall be entitled
at any time and from time to time to repurchase shares of Series&#160;D Preferred Stock in open-market transactions duly authorized
by the Board of Directors and effected in compliance with applicable laws.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(c)&#160;&#160;&#160;&#160;Notice
of redemption will be given by publication in a newspaper of general circulation in the City of New York, such publication to be
made once a week for two successive weeks commencing not less than 30 nor more than 60&#160;days prior to the redemption date.
A similar notice will be mailed by the Company, postage prepaid, not less than 30 nor more than 60&#160;days prior to the redemption
date, addressed to the respective holders of record of the Series&#160;D Preferred Stock to be redeemed at their respective addresses
as they appear on the stock transfer records of the Company. No failure to give such notice or any defect therein or in the mailing
thereof shall affect the validity of the proceedings for the redemption of any shares of Series&#160;D Preferred Stock except as
to the holder to whom notice was defective or not given. Each notice shall state: (i)&#160;the redemption date; (ii)&#160;the redemption
price; (iii)&#160;the number of shares of Series&#160;D Preferred Stock to be redeemed; (iv)&#160;the place or places where the
Series&#160;D Preferred Stock is to be surrendered for payment of the redemption price; and (v)&#160;that dividends on the shares
to be redeemed will cease to accrue on such redemption date. If less than all of the Series&#160;D Preferred Stock held by any
holder is to be redeemed, the notice mailed to such holder shall also specify the number of shares of Series&#160;D Preferred Stock
held by such holder to be redeemed.</P>



<P STYLE="text-indent: 0pt; margin-right: 0; margin-left: 0">&nbsp;</P>

<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(d)&#160;&#160;&#160;&#160;Immediately
prior to any redemption of Series&#160;D Preferred Stock, the Company shall pay, in cash, any accumulated and unpaid dividends
through the redemption date, unless a redemption date falls after a Dividend Record Date and prior to the corresponding Dividend
Payment Date, in which case each holder of Series&#160;D Preferred Stock at the close of business on such Dividend Record Date
shall be entitled to the dividend payable on such shares on the corresponding Dividend Payment Date notwithstanding the redemption
of such shares before such Dividend Payment Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(e)&#160;&#160;&#160;&#160;Excess
Shares may be redeemed, in whole or in part, at any time when outstanding shares of Series&#160;D Preferred Stock are being redeemed,
for cash at a redemption price of $25 per share, but excluding accrued and unpaid dividends on such Excess Shares, without interest.
Such Excess Shares shall be redeemed in such proportion and in accordance with such procedures as shares of Series&#160;D Preferred
Stock are being redeemed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(f)&#160;&#160;&#160;&#160;All
Series&#160;D Preferred Shares redeemed pursuant to this Section&#160;6 shall be retired and shall be reclassified as authorized
and unissued preferred shares, without designation as to class or series, and may thereafter be reissued as any class or series
of preferred shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">7.&#160;&#160;&#160;<B>Voting
Rights</B><I>.</I>&#160;&#160;&#160;&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(a)&#160;&#160;&#160;&#160;Holders
of the Series&#160;D Preferred Stock will not have any voting rights, except as set forth below.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(b)&#160;&#160;&#160;&#160;Whenever
dividends on any shares of Series&#160;D Preferred Stock shall be in arrears for any six or more quarterly dividend periods, regardless
of whether such quarterly periods are consecutive (a &#8220;<B>Preferred Dividend Default</B>&#8221;), the number of directors
then constituting the Board of Directors shall be increased by two (if not already increased by reason of a similar arrearage respect
to any Parity Preferred (as hereinafter defined). The holders of such shares of Series&#160;D Preferred Stock (voting separately
as a class with all other series of Preferred Stock ranking on a parity with the Series&#160;D Preferred Stock as to dividends
or upon liquidation (&#8220;<B>Parity Preferred</B>&#8221;) upon which like voting rights have been conferred and are exercisable)
will be entitled to vote separately as a class, in order to fill the vacancies thereby created, for the election of a total of
two additional directors of the Company (the &#8220;<B>Preferred Stock Directors</B>&#8221;) at a special meeting called by the
holders of record of at least 20% of the Series&#160;D Preferred Stock or the holders of record of at least 20% of any series of
Parity Preferred so in arrears (unless such request is received less than 90&#160;days before the date fixed for the next annual
or special meeting of the shareholders) or at the next annual meeting of shareholders, and at each subsequent annual meeting until
all dividends accumulated on such shares of Series&#160;D Preferred Stock and Parity Preferred for the past dividend periods and
the dividend for the then current dividend period shall have been fully paid or declared and a sum sufficient for the payment thereof
set aside for payment. In the event the directors of the Company are divided into classes, each such vacancy shall be apportioned
among the classes of directors to prevent stacking in any one class and to insure that the number of directors in each of the classes
of directors are as equal as possible. Each Preferred Stock Director, as a qualification for election as such (and regardless of
how elected) shall submit to the Board of Directors of the Company a duly executed, valid, binding and enforceable letter of resignation
from the Board of Directors, to be effective upon the date upon which all dividends accumulated on such shares of Series&#160;D
Preferred Stock and Parity Preferred for the past dividend periods and the dividend for the then current dividend period shall
have been fully paid or declared and a sum sufficient for the payment thereof set aside for payment, whereupon the terms of office
of all persons elected as Preferred Stock Directors by the holders of the Series&#160;D Preferred Stock and any Parity Preferred
shall, upon the effectiveness of their respective letters of resignation, forthwith terminate, and the number of directors then
constituting the Board of Directors shall be reduced accordingly. A quorum for any such meeting shall exist if at least a majority
of the outstanding shares of Series&#160;D Preferred Stock and shares of Parity Preferred upon which like voting rights have been
conferred and are exercisable are represented in person or by proxy at such meeting. Such Preferred Stock Directors shall be elected
upon the affirmative vote of a plurality of the shares of Series&#160;D Preferred Stock and such Parity Preferred present and voting
in person or by proxy at a duly called and held meeting at which a quorum is present. If and when all accumulated dividends and
the dividend for the then current dividend period on the Series&#160;D Preferred Stock shall have been paid in full or declared
and set aside for payment in full, the holders thereof shall be divested of the foregoing voting rights (subject to revesting in
the event of each and every Preferred Dividend Default) and, if all accumulated dividends and the dividend for the then current
dividend period have been paid in full or set aside for payment in full on all series of Parity Preferred upon which like voting
rights have been conferred and are exercisable, the term of office of each Preferred Stock Director so elected shall terminate.
Any Preferred Stock Director may be removed at any time with or without cause by, and shall not be removed otherwise than by the
vote of, the holders of record of a majority of the outstanding shares of the Series&#160;D Preferred Stock when they have the
voting rights described above (voting separately as a class with all series of Parity Preferred upon which like voting rights have
been conferred and are exercisable). So long as a Preferred Dividend Default shall continue, any vacancy in the office of a Preferred
Stock Director may be filled by written consent of the Preferred Stock Director remaining in office, or if none remains in office,
by a vote of the holders of record of a majority of the outstanding shares of Series&#160;D Preferred Stock when they have the
voting rights described above (voting separately as a class with all series of Parity Preferred upon which like voting rights have
been conferred and are exercisable). The Preferred Stock Directors shall each be entitled to one vote per director on any matter.</P>



<P>&nbsp;</P>



<P>&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(c)&#160;&#160;&#160;&#160;So
long as any shares of Series&#160;D Preferred Stock remain outstanding, the Company will not, without the affirmative vote or consent
of the holders of at least two-thirds of the shares of the Series&#160;D Preferred Stock outstanding at the time, given in person
or by proxy, either in writing or at a meeting (voting separately as a class):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 72pt">(i)&#160;&#160;&#160;&#160;&#160;amend,
alter or repeal the provisions of the Charter or the Articles Supplementary, whether by merger, consolidation or otherwise (an
 &#8220;<B>Event</B>&#8221;), so as to materially and adversely affect any right, preference, privilege or voting power of the Series&#160;D
Preferred Stock or the holders thereof;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 72pt">(ii)&#160;&#160;&#160;&#160;authorize,
create or issue, or increase the authorized or issued amount of, any class or series of shares of Preferred Stock or rights to
subscribe to or acquire any class or series of shares of Preferred Stock or any security convertible into any class or series of
shares of Preferred Stock, in each case ranking senior to the Series&#160;D Preferred Stock with respect to payment of dividends
or the distribution of assets upon liquidation, dissolution or winding up, or reclassify any shares of Preferred Stock into any
such shares; <I>provided, however</I>, that with respect to the occurrence of any Event set forth above, so long as the Series&#160;D
Preferred Stock (or any equivalent class or series of stock issued by the surviving corporation in any merger or consolidation
to which the Company became a party) remains outstanding with the terms thereof materially unchanged, the occurrence of any such
Event shall not be deemed to materially and adversely affect such rights, preferences, privileges or voting power of holders of
the Series&#160;D Preferred Stock; and <I>provided, further</I>, that (i)&#160;any increase in the amount of the authorized Preferred
Stock or the creation or issuance of any other series of Preferred Stock, or (ii)&#160;any increase in the amount of authorized
shares of such series, in each case ranking on a parity with or junior to the Series&#160;D Preferred Stock with respect to payment
of dividends or the distribution of assets upon liquidation, dissolution or winding up, shall not be deemed to materially and adversely
affect such rights, preferences, privileges or voting powers.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(d)&#160;&#160;&#160;&#160;The
foregoing voting provisions will not apply if, at or prior to the time when the act with respect to which such vote would otherwise
be required shall be effected, all outstanding shares of Series&#160;D Preferred Stock shall have been redeemed or called for redemption
upon proper notice and sufficient funds shall have been deposited in trust to effect such redemption.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 36pt">(e)&#160;&#160;&#160;&#160;Except
as expressly stated in these Articles Supplementary, the Series&#160;D Preferred Stock shall not have any relative, participating,
optional or other special voting rights and powers and the consent of the holders thereof shall not be required for the taking
of any corporate action, including but not limited to, any merger or consolidation involving the Corporation or a sale of all or
substantially all of the assets of the Corporation, irrespective of the effect that such merger, consolidation or sale may have
upon the rights, preferences or voting power of the holders of the Series&#160;D Preferred Stock.</P>


<P>&nbsp;</P>




<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">8.&#160;&#160;&#160;<I>
</I><B>Conversion</B><I>.</I>&#160;&#160;&#160;&#160;The Series&#160;D Preferred Stock is not convertible into or exchangeable
for any other property or securities of the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">9.&#160;&#160;&#160;<I>
</I><B>Restrictions on Ownership and Transfer</B><I>.</I>&#160;&#160;&#160;&#160;Once there is a completed public offering of the
Series&#160;D Preferred Stock, if the Board of Directors shall, at any time and in good faith, be of the opinion that actual or
constructive ownership of at least 9.9% or more of the value of the outstanding capital stock of the Company (&#8220;<B>Excess
Shares</B>&#8221;) has or may become concentrated in the hands of one owner, the Board of Directors shall have the power (i)&#160;by
means deemed equitable by the Board of Directors, and pursuant to written notice, to call for the purchase from any shareholder
of the corporation a number of shares of Series&#160;D Preferred Stock sufficient, in the opinion of the Board of Directors, to
maintain or bring the direct or indirect ownership of such beneficial owner to no more than 9.9% of the value of the outstanding
capital stock of the corporation, and (ii)&#160;to refuse to transfer or issue shares of Series&#160;D Preferred Stock to any person
whose acquisition of such Series&#160;D Preferred Stock would, in the opinion of the Board of Directors, result in the direct or
indirect ownership by that person of more than 9.9% of the value of the outstanding capital stock of the Company. The purchase
price for any shares of Series&#160;D Preferred Stock shall be equal to the fair market value of the shares reflected in the closing
sales price for the shares, if then listed on a national securities exchange, or if the shares are not then listed on a national
securities exchange, the purchase price shall be equal to the redemption price of such shares of Series&#160;D Preferred Stock.
Payment of the purchase price shall be made within thirty days following the date set forth in the notice of call for purchase
and shall be made in such manner as may be determined by the Board of Directors of the Company. From and after the date fixed for
purchase by the Board of Directors, as set forth in the notice, the holder of any shares so called for purchase shall cease to
be entitled to dividends, and other benefits with respect to such shares, excepting only the right to payment of the purchase price
fixed as aforesaid. Any transfer of Series&#160;D Preferred Shares that would create an actual or constructive owner of more than
9.9% of the value of the outstanding shares of capital stock of this Company shall be deemed void <I>ab initio </I>and the intended
transferee shall be deemed never to have had an interest therein. If the foregoing provision is determined to be void or invalid
by virtue of any legal decision, statute, rule or regulation, then the transferee of such Series&#160;D Preferred Shares shall
be deemed, at the option of the corporation, to have acted as agent on behalf of the Company in acquiring such shares and to hold
such shares on behalf of the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">Notwithstanding
anything herein to the contrary, the Company and its transfer agent may refuse to transfer any shares of Series&#160;D Preferred
Stock, passing either by voluntary transfer, by operation of law, or under the last will and testament of any shareholder if such
transfer would or might, in the opinion of the Board of Directors or counsel to the Company, disqualify the Company as a Real Estate
Investment Trust under the Internal Revenue Code. Nothing herein contained shall limit the ability of the corporation to impose
or to seek judicial or other imposition of additional restrictions if deemed necessary or advisable to preserve the Company&#8217;s
tax status as a qualified Real Estate Investment Trust. Nothing herein contained shall preclude settlement of any transaction entered
into through the facilities of the New York Stock Exchange.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-right: 0; margin-left: 0">10.&#160;&#160;&#160;<B>No
Preemptive Rights</B><I>.</I>&#160;&#160;&#160;&#160;No holder of Series&#160;D Preferred Shares shall be entitled to any preemptive
rights to subscribe for or acquire any unissued shares of Preferred Stock of the Company (whether now or hereafter authorized)
or securities of the Company convertible into or carrying a right to subscribe to or acquire shares of Preferred Stock of the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="margin: 0"></P>








<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ohi-20250606.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaeCabOdzZR+uYkxtmB1bdmarykgQdVaeCFXH2nGcRsD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ohi="http://omegahealthcare.com/20250606" elementFormDefault="qualified" targetNamespace="http://omegahealthcare.com/20250606">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://omegahealthcare.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ohi-20250606_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ohi-20250606_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ohi-20250606_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ohi-20250606_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://omegahealthcare.com/role/Cover" xlink:href="ohi-20250606.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://omegahealthcare.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OMEGA HEALTHCARE INVESTORS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000888491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3041398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">303 International Circle,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hunt Valley<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">427-1700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.10 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OHI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2517197d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://omegahealthcare.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ohi-20250606.xsd</File>
    <File>ohi-20250606_lab.xml</File>
    <File>ohi-20250606_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2517197d2_8k.htm">tm2517197d2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2517197d2_8k.htm": {
   "nsprefix": "ohi",
   "nsuri": "http://omegahealthcare.com/20250606",
   "dts": {
    "schema": {
     "local": [
      "ohi-20250606.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ohi-20250606_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ohi-20250606_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2517197d2_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://omegahealthcare.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2517197d2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2517197d2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-25-057298-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-057298-xbrl.zip
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MR)QFPBP/@@7 E,E (4-*APJAEY[7=PE8IAYB!)MCRMP28#?9I*"I"8@$JS&
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M[G&K*(C>[W)FDE!J45/L&(L%ITF49 E;_RI//D6";:VRB5P! 1O4-+050:
MVC(Y. B15CJ&X$X0!2&1'9&_!*@2"XG;AP?K;-\E=@5%OV$-!ZP, I)>>R8L
M,F <U2)0$8+R&+_8S--T2\2;X+&$>$((- ^ U-*'B!-DLA>J(M G6PL2;>7\
MN#^9KI9)1FTGEVV)LSD),%?-2$9Y$&P IDP6\C+$']#)].^K?R =Y;C[;_A2
M8)4[=K'?K#@%LD]95:X@Z+"H.;!(@D !]F72<,-1*46%UD=VJH992W.,<E<
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M4;-VUVBV#P'QSC$M1]9M9!O04*$N/!(D9)A(R!RI[Y'1178?'V09Q(IC$IM
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M1G,G(-BS'<6Y(L9ZC#8)?O')7(9NFOGT61Q&X),BU(SDM3E7KRL/B#8NHL]
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MT^AKYJ*Z<?FC&//T],S%0'14Z<O$?,^AF6M%')HYX,LX=/[0S=XG="\;-\L
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MS[\\?[ML&<\?7(JD.H8ZIG_[]D K_3]02P,$%     @ ,H#&6B@,?K[\<
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M_J^G3X./"0B=WX@FK^'!_YJA?H;WOPZ.2#,6O^$"1.R]#OY  PG^'#Q]*IF
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M9!)8#WV(F:6ZHJ$Q?S-,QZ1/S6\>[F!&GH.1?9"3E,?&BHR"(DF_JW%^(!+
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MXZN,4XH+FH>3T2<"?W)M<-H2@N"@@#%M<PBK*A(EA&]$1?2HHM+J&0^.T4N
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M>]&ZG7Y_L;&YU9BTJ(S<FE)4@+Q6)59:PDHU<["RZP[;]8)B%$DYXX<,HL*
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MAH_%_TUDB7./DG..,; W506X7_0G. *=WR!=,V?;ZV2M9&FL48*5R<##@-"
MO=E2U1?5"*RY:YUW0HU+;2E$LE:1I-V7;W9M6*AQZ7.7C1J*4J"H#4W9K8JH
MF-1*T3SELX: XT@$1NV7-8\:]JE43<,YC6Z]455!!392GE"'T"PM026R+@.^
MI^2)923J.)6]:Y9OJFK6W3=5ZI-=-0;Y"29KC+#O5+D^9_.\Q'[O#C>/0K>R
MX<"_7Q"I'3=L;[/3(;??1;7-!LSQCH<,/#N>Y1(%=09.NXLGRVP0UWP]DDOM
MRW?C./I:WO:0.$FOI$6_)]L(C2VK!.QB]#7?6G"%-=2!=:D9)4 DCB#:$B\%
M):H$]/*-X,#3@7Y+T]>Q,?=2PXJ%]H;:DXA>L5S,D\M%!VXHUH,S,,9R=OAU
MB>E%Q)E@"9&+\IH"'VIQI< Z1YY\K5L)U&P2-YCDKC&UV%2UYX\)S%H"\^5C
M O/NVA';[7.7=^^J7/*[WPFP<(4P!/Z%!J]*9QZ9^G?OM6 5SKW6.I[.M=#=
M8INEV>019P6IM*NIDNZ"YF*7; \H;2D(.Z9 S8^;).<HA9(*UPQ;YK@2\2RY
M-'T6%,&0LATQXC%%B5_2N01;>UVIX<(W!6[Q:,T5XZ[EL-=754>,)ID-V$C&
MB;E?OCC\$EBQHRMK/"H#8BB-23XXJ>;X65A-L"! 0"W#$JK<F(*;3%(5M\*!
M4\!)87!P?((P% Q).AXGH^@RP0YBBF*5-#^)&RD4$&5S+0&V".KN)@IIS4:$
M^HGN(%6TBM.*!6L*1 PK@H=N'%:=$6T]='-F5%9AV3ZUL@(PEBIFC\<#;PT/
M.[AZV0#X/!)C5U%35UN,H\LLY]2YD%!HC*10Q'1HZ9 2:4'V#Q72-45AF8$>
M+I(U:2CC =+V>__;;BLG*;4%(HFINJ<RS:33[*^?=DJ9F@(8TUB!)C[R/4'8
M@TS-<AR/@.1KLOZ5U8_W;QR/T*16R#QE](.GMM-A^-V"PQOB]26--3N2&_1V
M=MX*M9_I8&'U _]*V[_"KY:RS>:X?!Y?9M\KCM5\!'\JWZ$Q:K0,7VL1ZJ&S
MN]-#R*XW4$+ WP@?;N5W=V^CAZ3)ZD":K#80'_3![FTT%^P2&,N@[7"V<1FC
M2YH;&0?K3@[2-]>D?<H-2=WJ-[1WC.J();5)9EO(NYP*X>^,E=Z.?X"J+Q+Z
M."8_2EUMIW(A^?5&_949)Y?Q:KIK2(IB)L9CXX17S]W=8 NY;8(*!@T:YN]8
M@K/>;E]=N^!\1&YEF(6RX*ET>\#2K0;,U@])H2&S^KUCVK*D29K8 Q%/RHG
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MTOA,R6_!!U7 DF5]J')[VD.5M-I!&06T[ZQ"SF$0.QE$+'FNH3OB,VVL&2=
MR1)>()E6EME?W)+9+S$$3KB_S.T'8PE+"Y%:#H:;2E15E <]5$((ZDF)TZ+/
M42_,VJ*505D:?-0L%0164L2#:XDPS'(]#_1/8.=BE,@2=,$O=2>$]92/?IP#
M;FR*A+KSH)M B(B?*?*HU;I% U/R8PB@!:OZ[ERPJ H$O::?)C.;;D2?E671
ME[=B40809.:LFA)6<XC546>UG^$@F"M\@!RZA=_/XU^K!ISN<H&S-RZIW>[B
M3RJWL!$EUAT^\E02&)<G-%4"4:J:+O&92J)/KBGX?)8RU''TPW2\&CB5 DVS
M86Q8I.; Y$J/E%:\K]:CD=MN^< 9=*/0-?^,LVF4CV UK"*X1]77P]?4A@BO
MF$37#"^43&8FT(GP<KY8O2S>#^\1_XAS!'^5!!L[^M2GBN:MF[YX*2R436.N
MT\ 5$L/D2HCQ]Q=9A*\"/93>)&W8RFUW$*SIQ>3B(\;>_6"\W>Q*O[K5E=91
MW/<6@/D)\DT9O\86AC+/)$SD>/7R$9(%%0^C"EYX,AM0D4 1/ _63I#(8 IQ
M]5=P;(D!CF*\"-;4W[AG"@LTL:^9\J_6<@IJ\SS%)P<['J:0B=1[19'!&UD/
M2+&)^C06:UF:A(%T/1-09BFZ]TU\3AVIE&.%1:ER9;JB6"A(9D_(E2L9=ZPG
M*=VFT.&XT"#QX&?,#^AN7$^E,!4#\S:;\H!M*C8FA6W]7%AU$J'F=?=HXJ04
M<( !:$US4JO*[%N;MV+V/[!"18V/TQY%K?':,;@FT94H*ZZZ-%B?-IIVEMN8
M]RKV,!XG-#/G,N;B&&$[JR8Q"LXH\),SK*[N1B+324I>R&"F"L68\44R9XS9
MF$_:6UIM WN;N)69>@WW@ZT]5(.=-M+OJ9U$<%9_.I,CRJQTALCS!NP2(<JM
M%C(^E2KP=4FE*2?1N2]^NPVBKL(B[Z[A6)JX=#6:A%X])JKJB:JMQT357S-1
MI39[@[L%<E<FY?1[?QPL&ZO@=@O[?+#W[N#SP>D_^[V]PP_!P>&'_2^'!Q\/
MWN^='AP=W@^NP@T4X?.-S:U;*4(#*85R^G-BAQT<:XZ-AO%L,B$D%#*4401'
MI1.L$1]ADEBN_<B9AI&!"AFBTJ-B#_\T^C335A5EC?@K7O?%]C;3:^O%'NM-
MG .G;G5,A81I;,V(&T47.,<4/5MP3"86A5+K^116B!D,AA):A37XW,ZW4-82
MBR=P2I'T^G?<7A6TB4,7_+3$?HQ8 _R<2K)'#!D97VXJI\U6\%&8M"KOI=#I
M9FR^?2LV/X!W7Z2Z_-KGK'AB&(E\ZYH=B&AT2>Z[+J*AV3%%93Q6[9:P)Y^X
M*PBP$=M^*-K@YKFA=6F2PEP3FMB@[DE3Z$4O.VA;M;Z'-CJ%K)@0MXKJ&)M,
MHA8*[];Z<,%5E@7]@I$<G.X0*>;U8P#A$(IK:B&QW"8'MXI&O,AK+:>2+F^=
ML+;3KW8)!N;%=))=QU):CJ,?RZ8#\TJEE;T9.[>Z&?LZ [ 'I!XAN6NW VPV
M 46(U&>$<H@EKFUR 9KB!SI1&A)!++;4U&=[;-Z!'5V[9FD*1R?U:PSMIN67
M$;+4_F00#O7:EGI22[-W5LS@^7)P@F;OWN'^T;>3E;5O7MS*OM%,_D'//BMJ
MS+U7(,C;J#ZXBM(66)JC 3=HAF(%-,[\6< P"SM(A.AH0 ++IU73PYSY\@].
M<X'[1(X%@3E!P'HF.T%^DG7A^<C(^@QM7X>F(JOWW<R+4AE&*28EO<AZ;B+M
M__HGE5;E5H]^CP"_"8P.ITA%U)LYY" @#RI)],\3DMOJERQOAMS8+9\@#24%
MS6*:J=6NCI2WZ"T,Z9P(D;L6%;&D.*DY;$V"@[H@@2H!<%+T A]+,I-#AL5L
M*K-$L;*O.J5C%>G"L1\_58 #\(]-, .:#E*)%2NE-:I2YB]!"6PM:J## =X9
M+#DX1K4Z4T#VXV#KU<OG#''0M%.-K0'J%=.?R"0<[.>P79EMP%,QZT\3L#(W
M9&J-%1TQ4G!13;U&A45[S^N;&=8!TY*UF>?*ZD)*;I'0F,+/;,Y967$>07HV
MFXCOVKZ<U3QW:X"%?1/@Y.#/2F8K6 OT>^4#^-G <(D/1TID)L64$30JQP@Q
M,-#?-K8V31UCR-XD#_<QF5K?F!]OBM8:3.R(,CI?UX=8P0/0G@;2,]37SU*6
M=9_'/:;J1STJ=8@Z38^@HTQR2O6+-/\%B)0E)+2CPAZVY(DF-!0'[GC(;X:"
MXE^N#<QKDHI/Q2>D00OM)5V=9S:*P6@&"IUR8](R;PW&,)Z@9[UXC4E_K^+1
MNT/):L?&MX.QKZ-I@OF0INQ,)8UCD'1,4ZH#3$,TU) X:@6K0Z,W[Q29]J6V
M#9S$8>F7/">F$DY].MACAW3KU<XS6T.MS@X-%QQHMO?H7\1%T'^W0*7ACF1R
MN!RUM!N70P;4#)WF8]/ A3FT:PDI%;JWE4VX4DK'(\IXV^]6E;IV0[ S[''W
MV?9:1/W(\Q&35R*MMKWYF%:KI]6V']-J=S?A90G874L: [-<&8;1S0;OX4N4
M@Q\%TN=WKD)QU-9G#-G>TH%809&.-=L-Y,!E_#/+O[,IK156"%[6<!6WPM$-
MOV8RFBO4F$BD?K B22#;PX#C!UHG1::&*@S^1+M3K)HA3P6S>KQ(46D..,.2
MX/2"DH:J-OD,9!-]8YIAU?P03:39 %=EO#B=)K%49D'%,AF"/T92,HI>!$5[
M"FE+;%1T6SMK(X3^D&ZG,9>1V*;'2AYDU=IK]/4LJ$2_NV?LTB;';ZH?4??]
MMC8V-VEBH^/]!:[SASZ"-:=/*I8L5+6?TA?$&EK?55,G [IT(O<):^OA7YQ(
MP9NECM)"F?$X:P4S[<O=YSH^^O+Y9@>+[4'I8J?;&^1J'I]A[A!9SBJ)J_7!
MK. $CQ<;F]LW2TOL6>FJ>Y_:T;PY[QB/1?]+M;^VJ8#H(E3\4.HN[WJ$"".(
M2!00ZY.2BQ[R>!J3ZV378CK#IRNBPD&)PSG#5_@8U"3<&HXX)]*TC4 G8HU(
M:[H[4,=!A+(2G]3N/"%P297B07QV-=G!=N8I"F/W*;"RC+#K"U=23*ZK^$O5
M\>X<8Y%GP[M$,DN=C5/*4J<&#54M[#'>U/^-9Q%Y #@>DNU\8S<6_6^EA)=K
M=.L-9G4%H[H&FG(&P1H/Y^/:!@<ET/1J1*KUV\PSUE%1DPT#KJ-2AP57("A<
M<A_0@M(,F34WAU%;P';H!/N<GYK:J0;2K\6]4,G83*4P$]>:Q[F*OH8%614K
MOAIH2]@C<25M"L;IR\U?;EQ+O$),[4-)OY$L;:B<(2:HLA(F.4Q%MEUNCD3+
MU8GQI!<&.K-JV>6T',&"#5N>,AFPR"L5VMQ'80W=4/!Z5$1'IQ6ZYOCVT^?8
MK6BZ,%;'@JFH^=N5V?Q._@\*#?":==]<159CE]1PIJ+DHWB"+4^DYIC^)Z7
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MRY>HQ*Z?ZR[\0040[03$R T.NBB)42[DX5+B8-"!G93T-28LO]/(]%E*[3-
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M0NU?WQU]^">%TCZ=?OG\]O\#4$L! A0#%     @ ,H#&6II]JJ0K P  ] L
M !               ( !     &]H:2TR,#(U,#8P-BYX<V102P$"% ,4
M"  R@,9:)"[-C/P*  !_A@  %               @ %9 P  ;VAI+3(P,C4P
M-C V7VQA8BYX;6Q02P$"% ,4    "  R@,9:6]-8X%P'  #A5P  %
M        @ &'#@  ;VAI+3(P,C4P-C V7W!R92YX;6Q02P$"% ,4    "  R
M@,9:GQ-7U[ :  "MN@  $@              @ $5%@  =&TR-3$W,3DW9#)?
M.&LN:'1M4$L! A0#%     @ ,H#&6B@,?K[\<   R)<" !4
M ( !]3   '1M,C4Q-S$Y-V0R7V5X,RTQ+FAT;5!+!08     !0 % $4!   D
%H@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>tm2517197d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ohi-20250606.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000888491</identifier>
        </entity>
        <period>
            <startDate>2025-06-06</startDate>
            <endDate>2025-06-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-06" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2025-06-06" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-06" id="Fact000005">0000888491</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-06" id="Fact000011">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-06" id="Fact000012">2025-06-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-06" id="Fact000013">OMEGA HEALTHCARE INVESTORS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-06" id="Fact000014">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-06-06" id="Fact000015">1-11316</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-06" id="Fact000016">38-3041398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-06" id="Fact000017">303 International Circle,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-06-06" id="Fact000018">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-06" id="Fact000019">Hunt Valley</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-06" id="Fact000020">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-06" id="Fact000021">21030</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-06" id="Fact000022">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-06" id="Fact000023">427-1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-06" id="Fact000024">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-06" id="Fact000025">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-06" id="Fact000026">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-06" id="Fact000027">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-06-06" id="Fact000028">Common Stock, $.10 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-06-06" id="Fact000029">OHI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-06-06" id="Fact000030">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-06" id="Fact000031">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
